| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
IND Submission example | IND | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
IND Submission example | IND | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Enveric Biosciences, Inc.$1.32
-0.02 (-1.49%)
Market Cap
8.14 M
EPS
-27.35
P/E Ratio
-
Value Trade
247.59 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
345.97 K
Operating CF
-2.26 M
Total Assets
5.52 M
Total Liabilities
5.52 M
Equity
5.06 M
D/E Ratio
12,345
-1.34 %
Week
-33.03 %
1 Month
4.74 %
3 Month
-62.29 %
6 Month
-99.99 %
5 Year
-100 %
All Time
Cash Data
Cash Position
4.91 M
Monthly Burn
752.00 K
Runway
4.1 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
4.38 K
52 Week Range
1.71 - 17.64
% held by Insiders
2 %
% held by Institutions
9.58 %
Enterprise Value
3.23 M
Total Shares
3.68 M
Short %
0.51 %
Float Shares
3.62 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Enveric Biosciences, Inc.
245Total events
0Upcoming
35Tier-1 (high impact)
2005 – 2026Coverage
Event history 2
TBD
◆R&D DayPresentation
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EB-003 | PTSD | — | 2025-11-14 | significantly decreased context-induced freezing behavior one-hour post-dose (p < 0.05) Read More | Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional p Read More | |
EB-003 | PTSD | — | 2025-11-14 | significantly decreased context-induced freezing behavior one-hour post-dose (p < 0.05) Read More | Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional p Read More | |
EB-003 | PTSD | — | 2025-11-14 | significantly decreased context-induced freezing behavior one-hour post-dose (p < 0.05) Read More | Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional p Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ENVB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ENVB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ENVB▼ -1.5%today
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Enveric Biosciences has welcomed the FDA's finalized guidance on psychedelic drug development, which addresses key clinical challenges. The guidance emphasizes the importance of rigorous data generation for regulatory review. Enveric's EB-003 aims to engage neuroplasticity without inducing hallucinogenic experiences, potentially allowing for simpler trial designs and outpatient treatment options. The FDA's guidance is seen as a positive step towards the practical delivery of psychedelic therapies.
Read more →ENVBJoseph Tucker, Ph.D., CEO & Director, Enveric Biosciences [Big4Bio]
Joseph Tucker, CEO of Enveric Biosciences, discusses the company's unique approach in the psychedelic biotech sector. Unlike others, Enveric is focused on developing non-hallucinogenic compounds that can provide therapeutic benefits without the limitations of traditional psychedelic treatments. This strategy emphasizes rigorous medicinal chemistry to ensure scalability.
Read more →ENVBThe Next Evolution of Psychedelic Medicine May Not Be Psychedelic at All [Meditech Today]
The article discusses the evolution of psychedelic medicine, highlighting how researchers are moving beyond first-generation compounds. It emphasizes the potential for new, psychedelic-inspired therapies to transform mental healthcare. The focus is on innovative approaches that may not necessarily involve traditional psychedelics.
Read more →ENVBPsychedelic Nation? Psilocybin Treatments Offer New Hope for People Prozac Hasn’t Helped [The Daily Upside]
The article discusses the growing interest in psilocybin treatments for mental health, highlighting endorsements from notable figures like OpenAI CEO Sam Altman. It suggests that such psychedelic experiences may offer hope for individuals who have not found relief with conventional medications like Prozac. The trend is gaining traction among tech innovators and the broader public.
Read more →ENVBEnveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Enveric Biosciences announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026. CEO Joseph Tucker will engage in a Neuropsychiatry Fireside Chat, discussing trends in neuropsychiatry and the development of their lead candidate, EB-003. The company aims to address challenges in mental health drug development with promising preclinical data.
Read more →ENVBEnveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Enveric Biosciences has announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit. The event aims to focus on advancements in mental health and related therapies. Further details on the company's specific contributions or presentations at the summit were not provided.
Read more →ENVB▼ -7.4%on this news
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Enveric Biosciences has announced its participation in the 2026 BIO International Convention. The event is expected to provide a platform for networking and showcasing advancements in biotechnology. Further details regarding their participation and planned activities at the convention were not disclosed in the announcement.
Read more →ENVB▼ -8.6%on this news
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
Enveric Biosciences will participate in the UBS 3rd Virtual CNS Day. The event aims to discuss advancements in central nervous system therapies. Details regarding the company's presentation or specific topics have not been disclosed.
Read more →ENVBEnveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
Enveric Biosciences has commenced IND-enabling genotoxicity studies for its lead neuroplastogen candidate, EB-003. This marks a significant step in the drug development process, reflecting the company's commitment to ensuring the safety and efficacy of its therapeutic candidate. The studies are essential for regulatory approval.
Read more →ENVBTrump’s psychedelic drug order boosts investor interest with promise of faster reviews [Reuters]
President Trump's executive order aims to expedite the development of psychedelic drugs, generating optimism among companies in the sector. Enveric Biosciences reported a $5 million capital raise in response to the announcement. However, experts warn that while investor interest is rising, the actual availability of new treatments is still distant.
Read more →ENVBNew antidepressants: Tackling treatment resistant depression [LaBiotech]
The article discusses the global prevalence of depression, affecting about 5% of adults. It highlights various depressive disorders, including major depressive disorder and seasonal affective disorder, which can severely impact individuals' lives. The focus is on the development of new antidepressants aimed at treating those who are resistant to current treatments.
Read more →ENVBEnveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
Enveric Biosciences has announced positive preclinical results from a phototoxicity analysis of its lead neuroplastogen candidate, EB-003. This analysis is crucial for assessing the safety profile of the compound. The encouraging findings may pave the way for further development and potential clinical trials.
Read more →ENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Enveric Biosciences reported its Q1 2026 financial results, highlighting progress in the development of its lead candidate EB-003, which is moving towards first-in-human trials. The company has strengthened its intellectual property portfolio and reported positive preclinical data for EB-003. Despite a net loss of $1.6 million, Enveric remains optimistic about its future prospects in the mental health space.
Read more →ENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 Product Development Highlights: Continued advancement of lead candidate EB-003 with IND-enabling studies progressing towa
Enveric Biosciences (NASDAQ: ENVB) released its financial results and corporate updates for the first quarter of 2026, highlighting continued progress in the development of lead candidate EB-003. The company reported promising preclinical data, which suggests EB-003's effectiveness in providing rapid antidepressant and anxiolytic effects, particularly in PTSD. Additionally, Enveric has fortified its intellectual property portfolio and raised significant capital to support ongoing and future development efforts. Despite a reported net loss for the quarter, the company remains optimistic about its prospects.
Read more →ENVBEnveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
Enveric Biosciences has announced the issuance of a new U.S. patent that expands its intellectual property portfolio. This patent pertains to methods of treating psychiatric disorders, potentially enhancing the company's capabilities in this therapeutic area. The development is expected to bolster investor confidence and support future innovations.
Read more →ENVBExecutive Order For Psychedelics [Clinical Leader]
The White House has issued an executive order to expedite the research and clinical trials of psychedelics, including psilocybin, MDMA, and ibogaine. While this order aims to enhance the exploration of these substances in therapeutic contexts, it does not alter their current legal status. Joseph Tucker, CEO of Enveric Biosciences, discusses the implications for the industry.
Read more →ENVB▼ -8.6%on this news· ran to -19% by day 3shared move
The Neuroplastogen Bet: Inside the Science, the Hype, and the Unanswered Questions in Psychedelic-Inspired Medicine [Meditech Today]
The article discusses the evolving landscape of psychedelic medicine, highlighting a shift from traditional concepts to more pharmaceutical-like terminology. Terms such as 'receptor selectivity' and 'outpatient scalability' are becoming more common, indicating a potential transformation in the industry. The role of the psychedelic experience is also being reconsidered.
Read more →ENVBEnveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies [Benzinga]
Enveric Biosciences Inc. has reported promising preclinical results for its candidate EB-003, which demonstrated rapid reductions in fear responses associated with PTSD. The findings suggest that a single dose can significantly impact conditioned fear within an hour. This comes at a time when federal policies are increasingly supportive of psychedelic therapies for mental health.
Read more →ENVBPTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field [Microdose]
The psychedelic medicine sector is evolving, moving from experience-driven therapy to a more technical understanding of receptor pathways and neuroplastic mechanisms. This shift aims to enhance treatment for psychiatric diseases as 2026 approaches. Enveric's latest data signals a significant change in focus within the field.
Read more →ENVBEnveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
Enveric Biosciences has announced positive results for its drug candidate EB-003 in a preclinical model for PTSD. The findings suggest potential efficacy, paving the way for future research and development. This advancement highlights the company's commitment to addressing PTSD through innovative therapies.
Read more →ENVBTrump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map. [Microdose]
President Trump's April 2026 executive order aims to accelerate treatments for serious mental illnesses by prioritizing the review of psychedelic therapies by the FDA. This directive removes previous ambiguities in the regulatory pathway, promoting faster scheduling decisions and expanded access. The move is expected to enhance investor confidence and patient access to these therapies.
Read more →ENVB▼ -7.7%on this news· ran to +38% by day 3
Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum
Enveric Biosciences will participate in Needham's Virtual Psychedelics Forum, discussing non-hallucinogenic treatments for treatment-resistant depression. CEO Joseph Tucker will lead the panel on April 27, 2023. The event will also include one-on-one meetings with investors to outline the company's clinical development strategy and recent achievements.
Read more →ENVB▼ -7.7%on this news· ran to +38% by day 3shared move
Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum
Enveric Biosciences will have its CEO, Joseph Tucker, participate in a panel at Needham's Virtual Psychedelics Forum. The discussion will focus on non-hallucinogenic treatments for psychiatric conditions, particularly in relation to treatment-resistant depression. This participation highlights the company's commitment to advancing neuroplastogenic therapeutics.
Read more →ENVB▲ +100.5%on this newsshared move
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences has successfully closed a private placement, raising $5 million upfront, with potential additional proceeds of $8.9 million from warrants. The funds will be used for product development and general corporate purposes. The offering includes common stock and warrants, but there is no guarantee that the warrants will be exercised.
Read more →ENVB▼ -22.6%on this news· ran to +55% by day 1shared move
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences has announced a private placement to raise up to $13.9 million, including $5 million upfront and potential additional proceeds from warrants. The offering involves the sale of shares and warrants priced at $2.25 per share. The funds will be used for product development and working capital, with the closing expected around April 17, 2026.
Read more →ENVB▲ +8.4%on this news· ran to +20% by day 1
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
Enveric Biosciences has secured a new U.S. patent for its EVM301 Series, enhancing its intellectual property portfolio. The patent covers chemical compounds and methods for treating neurological disorders. The lead candidate, EB-003, is aimed at addressing mental health issues without hallucinogenic effects. The company is focused on advancing EB-003 towards a Phase 1 clinical trial.
Read more →ENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
Enveric Biosciences reported its financial results for Q4 and the fiscal year 2025, highlighting advancements in its lead candidate EB-003, aimed at treating mental health disorders. The company is preparing for an IND application to the FDA, supported by promising research findings. However, it also noted a net loss of $4.0 million for the quarter.
Read more →ENVB▲ +5%on this news
Hope For Non-Hallucinogenic Neuroplastogens [Drug Discovery Online]
Enveric Biosciences is working on non-hallucinogenic neuroplastogens as a safer alternative to psychedelics. These compounds aim to maintain therapeutic neuroplasticity signaling while minimizing the risk of hallucinations. CEO Joseph Tucker discusses the potential benefits of this innovative approach in drug development.
Read more →ENVBThe Patent War That Wasn’t: How Enveric’s Legal Win Reframes the Neuroplastogen Race [Pharma Tech News]
Enveric Biosciences announced a legal victory as a Post Grant Review petition against its U.S. Patent No. 12,138,276 was formally withdrawn. The petition was initially filed by Gilgamesh Pharmaceuticals and later inherited by AbbVie Inc. after its acquisition of Gilgamesh. This outcome potentially strengthens Enveric's position in the neuroplastogen market.
Read more →ENVB▲ +9.1%on this newsshared move
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
Enveric Biosciences announced the withdrawal of a Post-Grant Review petition against its U.S. Patent No. 12,138,276, filed by Gilgamesh Pharmaceuticals. This withdrawal follows Enveric's successful request for discretionary denial of the petition. With no remaining challenges, Enveric's patent protection for its neuroplastogenic therapeutics is now secure.
Read more →ENVB▲ +9.1%on this newsshared move
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested [Benzinga]
Enveric Biosciences announced that Gilgamesh Pharmaceuticals has withdrawn its Post-Grant Review petition against Enveric's U.S. Patent No. 12,138,276. This decision leaves Enveric's patent claims uncontested, following a recent $1.2 billion deal with AbbVie. The withdrawal marks a significant milestone for Enveric in securing its intellectual property.
Read more →ENVB▲ +9.1%on this newsshared move
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy [Microdose]
Enveric Biosciences has successfully navigated a potential setback as AbbVie withdrew its Post Grant Review petition against one of its key U.S. patents. This patent, which covers halogenated psilocybin derivatives, now faces no remaining challenges. This development is significant for Enveric's strategy in the neuroplastogen sector.
Read more →ENVB▲ +6.8%on this newsshared move
What Enveric Biosciences’ EB-003 data reveal about separating benefit from hallucinations [Pharma Device News]
Enveric Biosciences has released new data on its lead candidate EB-003, which shows engagement with Gq and β-arrestin signaling downstream of the 5-HT2A receptor. This data supports the development of EB-003 as a non-hallucinogenic therapy for treating depression and anxiety. The company is currently advancing EB-003 through IND-enabling studies.
Read more →ENVB▲ +8%on this newsshared move
Beyond the Trip: Enveric’s EB-003 and the Next Phase of Psychedelic-Inspired Drug Design [Meditech Today]
Enveric's EB-003 highlights a shift in psychedelic research, emphasizing the importance of intracellular signaling over the subjective experience of psychedelics. This approach may lead to innovative drug designs that reshape neural circuits, indicating a promising future for therapeutic applications. The article discusses the evolving landscape of psychedelic-inspired drug development.
Read more →ENVB▲ +8%on this newsshared move
Enveric Biosciences stock soars after revealing new data on lead drug candidate [Investing.com]
Enveric Biosciences' stock experienced a significant increase of 13.4% following the announcement of new mechanistic data for its lead drug candidate, EB-003. This data highlights the compound's ability to activate dual signaling pathways associated with antidepressant and anxiolytic effects. The positive market reaction reflects investor confidence in the drug's potential.
Read more →ENVB▲ +8%on this newsshared move
Breaking News: Enveric Unveils Proprietary Receptor Data That Could Redefine Psychedelic Drug Design [Medium]
Enveric Biosciences has released new mechanistic data on its lead candidate, EB-003. This data provides insights into how next-generation neuroplastogens can differentiate therapeutic benefits from hallucinogenic risks. The findings could significantly impact the design of psychedelic drugs.
Read more →ENVB▲ +8%on this newsshared move
Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals [Benzinga]
Enveric Biosciences has released new mechanistic data indicating that its lead drug candidate, EB-003, activates both Gq- and β-arrestin-mediated signaling through the 5-HT2A receptor. This drug is designed as a non-hallucinogenic neuroplastogen, aiming to facilitate streamlined treatment options, including the possibility of at-home administration.
Read more →ENVB▲ +8%on this newsshared move
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
Enveric Biosciences announced new data on its lead candidate, EB-003, demonstrating its ability to activate both Gq and β-arrestin signaling pathways linked to antidepressant and anxiolytic effects. The findings, supported by independent studies, suggest that therapeutic benefits can be achieved without hallucinations. Enveric plans further testing to explore these mechanisms.
Read more →ENVB▲ +7.7%on this newsshared move
The next wave of psychedelics focuses on brain rewiring without the trip [Drug Discovery News]
The article discusses the evolving landscape of psychedelics, particularly their potential to rewire the brain without the hallucinogenic effects. Clinical trials have demonstrated their effectiveness in treating mental health issues such as depression, anxiety, and PTSD. However, the article also notes that there are still concerns regarding the use of these substances.
Read more →ENVB▼ -11%on this news
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development [Microdose]
Recent studies are shifting the focus of psychedelic drug development from clinical outcomes to understanding the underlying mechanisms. This change is driven by promising results in treating conditions like depression, anxiety, and trauma with compounds such as psilocybin and LSD. However, questions remain about the specific receptors involved and the necessity of intense altered states for therapeutic benefits.
Read more →ENVB▼ -7.4%on this news· ran to -24% by day 3shared move
A New Era For Psychedelic Therapeutics [Drug Discovery News]
The article discusses the rising interest in psychedelic therapeutics, highlighting the positive outcomes from clinical trials involving substances like psilocybin and MDMA. It notes the significant investment in this sector, which has led to the rapid emergence of numerous biotech and pharmaceutical companies. The psychedelic industry is now recognized as a multibillion-dollar market with promising growth potential.
Read more →ENVB▼ -12%on this news
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
Enveric Biosciences has announced an expansion of its collaboration with TOTEC Pharma through a trademark license for the RCANN portfolio. This agreement allows TOTEC to advance the commercialization of patented cannabinoid crème technology for treating radiation dermatitis. The deal includes an option for TOTEC to purchase the trademark in the future, contingent on meeting specific milestones.
Read more →ENVB▼ -12%on this newsshared move
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences has successfully closed a registered direct offering, raising approximately $1.5 million through the sale of 328,802 shares at $4.41 each. The company also issued unregistered warrants in a concurrent private placement. Proceeds will be used for product development and general corporate purposes.
Read more →ENVB▼ -12%on this newsshared move
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences has announced a registered direct offering of 328,802 shares at $4.41 each, aiming to raise approximately $1.5 million. The funds will be used for product development and general corporate purposes. The offering includes unregistered warrants with specific exercise prices and terms. The closing is expected around January 28, 2026, pending customary conditions.
Read more →ENVB▼ -9.5%on this news
Enveric Biosciences Announces Patent Issuance
Enveric Biosciences has announced the issuance of U.S. Patent No. 12,492,179, which expands its pipeline of neuroplastogenic small-molecule therapeutics aimed at treating neuropsychiatric conditions. The patent strengthens the company's intellectual property and opens new avenues for developing and licensing innovative treatments. CEO Joseph Tucker highlighted the potential for these novel molecules to outperform existing therapies.
Read more →ENVB▲ +5.5%on this news
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward [Microdose]
The article discusses the evolution of the psychedelic industry from 2024 to 2025, highlighting a shift from ambitious promises to a focus on trial design, regulatory compliance, and safety. This transition is seen as a positive development that clarifies the industry's direction and enhances its credibility.
Read more →ENVBEnveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
Enveric Biosciences has successfully closed the exercise of warrants, generating approximately $3.1 million in gross proceeds. The warrants, originally set at higher exercise prices, were exercised at a reduced price of $7.05 per share. The company plans to utilize the funds for product development and general corporate purposes.
Read more →ENVB▼ -42.5%on this newsshared move
Enveric Biosciences skyrockets on patent allowance for psychedelic-inspired molecules [Mugglehead Magazine]
Enveric Biosciences Inc has received a notice of allowance from the United States Patent and Trademark Office for its EVM301 non-psychoactive, psychedelic-inspired drugs. This patent allowance indicates that the agency views the application positively, paving the way for potential advancements in the company's drug development.
Read more →ENVB▼ -47.3%on this newsshared move
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
Enveric Biosciences, Inc. announced the exercise of certain outstanding warrants, resulting in gross proceeds of approximately $3.1 million. This financial move, facilitated by definitive agreements and reduced exercise prices, is intended to support the company's product development and general corporate needs. The offering is set to close on December 12, 2025, subject to customary conditions. Enveric focuses on the development of innovative therapeutics targeting psychiatric and neurological disorders.
Read more →ENVBEnveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
Enveric Biosciences has received a Notice of Allowance from the USPTO for its EVM301 Series patent application. This patent will enhance the company's portfolio of neuroplastogenic molecules aimed at treating neuropsychiatric disorders. The lead candidate, EB-003, is designed to engage specific receptors for effective treatment without hallucinogenic effects.
Read more →ENVBEnveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”
Enveric Biosciences will present at the Sachs Associates 9th Annual Neuroscience Innovation Forum during J.P. Morgan Week 2026 in San Francisco. The company aims to showcase its business strategy and clinical developments while participating in one-on-one meetings with investors. Enveric focuses on developing small-molecule therapeutics for psychiatric and neurological disorders.
Read more →ENVBEnveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”
Enveric Biosciences will present at the Sachs Associates 9th Annual Neuroscience Innovation Forum during J.P. Morgan Week 2026 in San Francisco. The company aims to showcase its business strategy and clinical developments while engaging with investors and partners. Additionally, Enveric will attend the Biotech Showcase 2026, further promoting its neuroplastogenic therapeutics.
Read more →ENVBThe Quiet Race Reshaping Psychedelic Medicine [Meditech Today]
The article discusses the evolving landscape of psychedelic medicine, emphasizing the potential benefits of guided psychedelic experiences in treating mental health issues like depression, trauma, and addiction. Despite the surge in research and interest surrounding substances like psilocybin and MDMA, the adoption of these treatments by larger patient populations remains a challenge.
Read more →ENVBHealing A Broken Mental Health System: Dr Joseph Tucker of Enveric Biosciences On 5 Things That Can Be Done To Fix Our Broken Mental Health System [Medium]
The article discusses the urgent need for reform in the mental health system, emphasizing the insights of Dr. Joseph Tucker from Enveric Biosciences. It highlights the ongoing challenges faced by individuals and families in accessing mental health support. The piece is part of a broader interview series aimed at gathering perspectives from various stakeholders in behavioral health.
Read more →ENVBDelix Therapeutics Reports Strong Phase Ib Results [Microdose]
Delix Therapeutics has reported promising results from its Phase Ib trial of DLX-001, a non-hallucinogenic neuroplastogen. The trial demonstrated significant biomarker signals indicating neuroplasticity engagement and showed rapid, lasting antidepressant effects in adults suffering from major depressive disorder. This development marks a positive step forward in the treatment of MDD.
Read more →ENVBEnveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
Enveric Biosciences has received a fourth Notice of Allowance from the USPTO for its EVM401 Series of drug candidates aimed at treating mental health disorders. This patent will expand Enveric's pipeline by including additional neuroplastogenic molecules. The company emphasizes its commitment to developing non-hallucinogenic therapeutics for neuropsychiatric conditions.
Read more →ENVBEnveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
Enveric Biosciences reported its Q3 2025 financial results, highlighting progress towards clinical readiness for its lead candidate EB-003, which targets neuropsychiatric disorders. The company announced positive preclinical data for PTSD and completed key milestones in manufacturing and regulatory processes. However, it also reported a net loss of $3.4 million and faced a delisting determination from Nasdaq due to bid price deficiencies.
Read more →ENVBEnveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional p
Enveric Biosciences (NASDAQ: ENVB) announced its Q3 2025 financial results, highlighting continued progress towards clinical trials for its lead candidate, EB-003, aimed at neuropsychiatric conditions. The company reported positive preclinical data demonstrating the efficacy of EB-003 in a model of PTSD, while also completing essential studies for drug development. However, Enveric faced a net loss of $3.4 million during the quarter, reflecting its ongoing financial challenges as it prepares for the IND submission necessary for advancing its pipeline.
Read more →ENVB▼ -8.3%on this news
Enveric Biosciences Announces Reverse Stock Split
Enveric Biosciences announced a reverse stock split of its common stock at a 1-for-12 ratio, effective October 28, 2025. This decision follows a delisting determination from Nasdaq due to failure to maintain the required minimum bid price. The split aims to help maintain the company's listing status while ensuring stockholder interests remain unchanged, barring fractional shares.
Read more →ENVB▼ -8.3%on this newsshared move
Enveric Biosciences Announces Reverse Stock Split Common Stock Will Begin Trading on a Split-Adjusted Basis on
Enveric Biosciences announced a reverse stock split, changing its common stock trading ratio to 1-for-12 as of October 28, 2025. This decision follows a delisting determination from Nasdaq due to failure to meet minimum bid price requirements. Despite this, the company intends to maintain its focus on developing neuroplastogenic therapeutics for psychiatric and neurological disorders. Shareholders will see their shares automatically adjusted to reflect the new ratio, though some may end up with fractional shares in the process.
Read more →ENVB▼ -12.4%on this news· ran to -25% by day 3
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
Enveric Biosciences has announced the issuance of its 23rd U.S. patent for novel neuroplastogenic compounds, aimed at treating psychiatric and neurological disorders. This patent expands Enveric's intellectual property estate and supports its pipeline of next-generation therapeutics. The company continues to focus on developing small-molecule drugs that promote neuroplasticity without hallucinogenic effects.
Read more →ENVB▲ +11.1%on this newsshared move
Enveric Hires Fish & Richardson To Defend IP Against Petition Claiming Its Patent Contains Claims Relevant To AbbVie’s $1.2B Bretisilocin Acquisition [Benzinga]
Enveric Biosciences has engaged Fish and Richardson P.C. to defend its U.S. Patent No. 12,138,276 against a Post-Grant Review petition from Gilgamesh Pharmaceuticals. The patent concerns halogenated psilocybin derivatives and their applications. This move underscores Enveric's commitment to protecting its intellectual property amidst competitive pressures.
Read more →ENVB▲ +24.4%on this newsshared move
AbbVie Could Face Patent Battle Over Depression Asset Gained in Gilgamesh Deal [SeekingAlpha]
Enveric Biosciences is considering legal action against AbbVie, claiming that AbbVie's candidate for major depressive disorder, bretisilocin, infringes on a patent held by Enveric. This candidate was part of a deal AbbVie made with Gilgamesh Pharmaceuticals for up to $1.2 billion. The situation may complicate AbbVie's plans in the depression treatment market.
Read more →ENVB▲ +24.4%on this newsshared move
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch [Microdose]
The article discusses the competitive landscape in the biotech sector, particularly focusing on Enveric Biosciences and its role in the burgeoning field of psychedelic-inspired therapeutics. It emphasizes the importance of intellectual property battles and regulatory challenges that accompany large acquisitions in this space. The narrative suggests that these factors will significantly influence the future of mental health treatments.
Read more →ENVB▲ +24.4%on this newsshared move
Enveric Biosciences Hires Fish & Richardson to Defend Patent Tied to AbbVie Deal [Investing.com]
Enveric Biosciences has engaged Fish and Richardson P.C. to defend against a Post-Grant Review petition from Gilgamesh Pharmaceuticals. This petition arises following Gilgamesh's agreement to be acquired by AbbVie for up to $1.2 billion. The move underscores Enveric's commitment to protecting its intellectual property.
Read more →ENVB▲ +24.4%on this newsshared move
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
Enveric Biosciences has hired Fish and Richardson P.C. to defend its U.S. Patent No. 12,138,276 against a Post-Grant Review petition from Gilgamesh Pharmaceuticals. This patent includes claims relevant to Bretisilocin, which AbbVie recently acquired. Enveric's patent portfolio is extensive, with multiple patents and pending applications, supporting its diverse product pipeline aimed at psychiatric disorders.
Read more →ENVB▲ +12.1%on this news· ran to +39% by day 1shared move
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
Enveric Biosciences has authorized its Capital Markets Committee to explore Digital Asset Treasury opportunities to enhance shareholder value. This initiative is part of the company's strategy to support long-term growth while continuing to focus on its core biotechnology programs. Updates will be provided as developments occur.
Read more →ENVB▼ -11.3%on this news· ran to +28% by day 3shared move
After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma? [Microdose]
AbbVie has made a significant investment of $1.2 billion in Gilgamesh Pharmaceuticals for Bretisilocin, indicating a shift in the perception of psychedelic therapies. These treatments are now considered a promising avenue in psychiatry, focusing on rebuilding neural architecture rather than merely adjusting serotonin levels. This marks a notable evolution in mental health treatment strategies.
Read more →ENVB▼ -11.3%on this news· ran to +28% by day 3shared move
How Enveric Biosciences Is Prepping For Its First IND [Clinical Leader]
Enveric Biosciences is preparing to submit its first Investigational New Drug (IND) application to the FDA for EB-003, a novel neuroplastogen. This therapy aims to provide a fast-acting, non-hallucinogenic treatment for conditions such as post-traumatic stress disorder, treatment-resistant depression, and generalized anxiety. The company previously opted out of a Phase 1 trial in Australia.
Read more →ENVB▲ +17.4%on this news
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
Enveric Biosciences has made significant advancements in the chemistry, manufacturing, and controls (CMC) of its lead candidate, EB-003, moving closer to initiating human clinical trials. Key achievements include the production of a pharmaceutically compatible salt form and a scalable synthetic route. These milestones are crucial for the upcoming Investigational New Drug (IND) application and GLP toxicology studies.
Read more →ENVBThe Next Chapter in Psychedelic Medicine: How Enveric Biosciences Stands Apart [HoneySuckle]
Enveric Biosciences is at the forefront of developing non-hallucinogenic therapies known as neurostabilogens. The company is advancing its lead candidate, EB-003, with the support of expedited FDA guidance. This positions Enveric as a viable alternative to traditional psychedelic treatments, emphasizing scalability and practicality.
Read more →ENVBEnveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Enveric Biosciences has successfully closed the exercise of certain series A and B warrants, generating approximately $2.2 million in gross proceeds. The company plans to utilize these funds for product development and general corporate purposes. Additionally, new series C and D warrants have been issued, which will provide further opportunities for capital.
Read more →ENVB▼ -29.3%on this newsshared move
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
Enveric Biosciences has published two peer-reviewed articles detailing novel bioproduction methods for neuropsychiatric drug discovery. The studies highlight the production of tryptamine derivatives and MDMA through engineered microbial systems, showcasing the potential for creating diverse therapeutic compounds. These advancements support Enveric's mission to develop innovative treatments for psychiatric disorders.
Read more →ENVB▼ -29.3%on this newsshared move
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Enveric Biosciences, Inc. has announced the exercise of certain series A and B warrants, resulting in gross proceeds of approximately $2.2 million. The immediate exercise comprises 1,212,499 shares at a reduced exercise price of $0.915 per share. The company plans to use the net proceeds for product development, working capital, and general corporate purposes. Additionally, Enveric will issue new unregistered series C and D warrants as part of this offering, with exercise prices set at $0.915 and different expiration terms.
Read more →ENVBWith big pharma circling psychedelics, the next breakthrough may not come from tripping at all [Microdose]
AbbVie has acquired Gilgamesh Pharmaceuticals for over $1 billion, signaling a significant shift in the biotech sector towards psychedelic-inspired drug development. This move reflects a growing belief in the potential of neuroplastogens, which are believed to help repair brain circuits affected by psychiatric conditions. The acquisition marks a pivotal moment for the integration of psychedelics into mainstream medicine.
Read more →ENVBEnveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
Enveric Biosciences has received a positive response from the FDA regarding its pre-IND meeting for EB-003, allowing the company to proceed directly to the IND application. This decision is seen as a significant step in advancing their lead neuroplastogen candidate, which aims to treat psychiatric disorders without hallucinogenic effects. The company is optimistic about its clinical development strategy.
Read more →ENVBEnveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
Enveric Biosciences announced that CEO Joseph Tucker will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025. The presentation will cover updates on the company's pipeline, including lead candidate EB-003, designed to treat psychiatric disorders while minimizing hallucinatory effects. Dr. Tucker will also engage in one-on-one meetings with investors to discuss the company's strategies and milestones.
Read more →ENVBEnveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
Enveric Biosciences has relocated its corporate headquarters to Cambridge, MA, to leverage the area's biotech ecosystem. This move aims to enhance collaboration, attract talent, and increase visibility in the life sciences sector. The company is preparing to advance its lead candidate, EB-003, into first-in-human trials anticipated in 2026.
Read more →ENVBEnveric Biosciences Relocates Corporate Headquarters to Cambridge, MA Move aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance EB-003 into first-in-hum
Enveric Biosciences has announced its relocation of corporate headquarters to Cambridge, Massachusetts. This strategic move aligns with the company's vision to better leverage the Greater Boston biotech ecosystem, enhancing collaboration, talent acquisition, and visibility. Enveric aims to advance its lead candidate, EB-003, into first-in-human clinical trials anticipated for 2026, with potential benefits for neuropsychiatric conditions. The company underscores the importance of its new location in accessing scientific innovation and industry leadership.
Read more →ENVBAbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush? [Microdose]
AbbVie has acquired Gilgamesh Pharmaceuticals for nearly $1 billion, marking a significant entry of Big Pharma into the psychedelic sector. This acquisition not only makes headlines but also indicates a growing interest in neuroplastogens and their potential in mental health treatments. The move could inspire further investments in psychedelic research and development.
Read more →ENVB▼ -13.1%on this news· ran to -28% by day 3shared move
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
Enveric Biosciences has completed preclinical Dose Range Finding studies for its lead candidate EB-003, targeting neuropsychiatric disorders. The studies established the Maximum Tolerated Dose, which supports the progression towards IND-enabling studies and First-in-Human clinical trials. The findings indicate the drug's oral bioavailability and potential therapeutic effects without inducing hallucinations.
Read more →ENVBReimagining Psychedelics: Mental Wellness Without the Roadblocks [Pharmaceutical Online]
The article discusses the historical and cultural significance of psychedelic drugs, highlighting their medicinal and spiritual uses across various cultures. It emphasizes the renewed interest in psychedelics for mental wellness and their potential integration into modern medicine. The piece suggests a positive outlook on the future of psychedelics in therapeutic contexts.
Read more →ENVBEnveric Biosciences: Poised to Outshine Traditional Psychedelic Targets [Microdose]
Enveric Biosciences is gaining attention in the psychedelic therapeutics sector as it focuses on non-hallucinogenic neuroplastogens. This innovative approach aims to promote neuroplasticity without psychoactive effects, potentially making psychedelic-like benefits more accessible. The recent acquisition rumors in the sector have also heightened investor interest in companies like Enveric.
Read more →ENVBThe Future Of Psychedelic-Inspired Therapeutics: No-Trip Neuroplastogens [Life Science Leader]
The article discusses the advancements in psychedelic-inspired therapeutics during the ongoing psychedelic renaissance. It highlights the progress made in understanding brain targeting for mental healthcare, while also noting the challenges faced in navigating FDA oversight and the complexities of clinical development. Despite these hurdles, the excitement around this field continues to grow.
Read more →ENVBEnveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
Enveric Biosciences reported its second quarter 2025 financial results, highlighting significant advancements in the development of its lead drug candidate, EB-003. The drug demonstrates a dual mechanism of action targeting 5-HT A and 5-HT B receptors, positioning it as a potential first-in-class treatment for psychiatric disorders. The company is preparing for an IND submission in early 2026 while expanding its intellectual property portfolio.
Read more →ENVBEnveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results Q2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling pro
Enveric Biosciences reported its financial and corporate results for the second quarter of 2025, highlighting the critical progress in the development of EB-003. The drug's unique dual mechanism of action at the 5-HTA and 5-HTB receptors positions it as a promising candidate for addressing psychiatric and neurological disorders. Despite a net loss of $2.5 million for the quarter, the company is focused on furthering its IND application and strengthening its intellectual property portfolio. The outlook remains positive with ongoing interest from pharmaceutical companies in the neuropsychiatry space.
Read more →ENVBSix psychedelic drug companies aiming to revolutionize mental health treatment [Labiotech]
The article discusses the potential of psychedelic drugs as effective treatments for severe mental health issues, particularly depression. It highlights six leading companies in the psychedelic medicine sector, each focusing on different niches. The exploration of these companies underscores the growing interest and investment in psychedelic therapies for mental health.
Read more →ENVBEnveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Enveric Biosciences has received a second Notice of Allowance from the USPTO for its EVM401 Series, which includes novel non-hallucinogenic mescaline derivatives aimed at treating psychiatric disorders. This patent strengthens Enveric's position in developing neuroplastogenic therapeutics. The compounds are inspired by methylone but are structurally unique, allowing for patent protection and potential outpatient use.
Read more →ENVBStimulating Neuroplasticity for Therapeutic Benefits Inspired by Psychedelic Research [High on Healthy]
Dr. Joseph Tucker, CEO of Enveric Biosciences, discusses the company's innovative approach to developing non-hallucinogenic neuroplastogens. These compounds are inspired by psychedelic research and aim to stimulate neuroplasticity, potentially offering significant therapeutic benefits. The conversation highlights the intersection of neuroscience and psychedelic studies in modern medicine.
Read more →ENVBEnveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment [Microdose]
Enveric Biosciences has announced promising results for its lead drug candidate, EB-003, in a preclinical model for post-traumatic stress disorder (PTSD). This condition affects nearly 13 million Americans annually. The drug demonstrated a rapid therapeutic effect, suggesting it could offer a new direction in trauma treatment amidst the ongoing mental health crisis.
Read more →ENVB▼ -8.2%on this newsshared move
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
Enveric Biosciences announced positive preclinical results for EB-003, its lead drug candidate for PTSD. The study demonstrated that EB-003 significantly reduced freezing behavior in a rodent model, indicating its potential as a therapeutic agent. This finding suggests EB-003 may offer a novel treatment option for PTSD, addressing a significant unmet need in mental health care.
Read more →ENVBEB-003 Targets 5‑HT1B: Expanding Mental Health Promise [Meditech Today]
Enveric Biosciences has revealed new data on EB-003, its lead neuroplastogen, which acts as an agonist at the serotonin 5-HT1B receptor. This discovery expands the therapeutic potential of EB-003 to include treatment for depression, Parkinson's disease, and migraines. The compound is positioned as a prescription-ready neuroplastogenic agent.
Read more →ENVBEnveric’s EB-003 Shows Dual Mechanism Promise, Paving a New Path in Neuropsychiatric Drug Innovation [Microdose]
Enveric Biosciences is advancing its lead candidate, EB-003, which aims to enhance neuroplasticity while avoiding the hallucinogenic effects associated with traditional psychedelics. The recent data released on June 24 suggests significant potential for both commercial and therapeutic applications. This positions Enveric as a potential leader in neuropsychiatric drug development.
Read more →ENVBEnveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003
Enveric Biosciences announced that its lead candidate, EB-003, acts as an agonist of the serotonin receptor 5-HT1B, expanding its potential clinical applications. This receptor is linked to treating major depressive disorder and other neurological conditions. The findings complement existing data on EB-003's engagement with the 5-HT2A receptor, supporting its neuroplastogenic effects without adverse outcomes. The compound is currently in preclinical development with plans for IND-enabling activities through 2025.
Read more →ENVBEnveric Biosciences Announces Participation in 2025 BIO International Convention
Enveric Biosciences announced its participation in the upcoming BIO International Convention scheduled for June 16-19, 2025, in Boston. CEO Joseph Tucker will hold one-on-one meetings with investors to discuss the company's strategies and milestones. Enveric focuses on developing novel therapeutics for psychiatric and neurological disorders, including its lead candidate EB-003.
Read more →ENVBEnveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
Enveric Biosciences has announced the receipt of a Notice of Allowance from the USPTO for a patent covering a new class of aminated tryptamine derivatives. These compounds are designed to be non-hallucinogenic, offering a novel approach to treating psychiatric disorders like depression and PTSD. The patent strengthens Enveric's position in developing next-generation mental health therapeutics.
Read more →ENVBEnveric’s Patent Win Targets New Frontiers in Sleep Medicine [Microdose]
Enveric Biosciences has been granted U.S. Patent No. 12,187,679, which covers a new class of hydroxylated psilocybin derivatives. These derivatives selectively target melatonin MT1 receptors, which are crucial for regulating sleep-wake cycles and circadian rhythms. This patent strengthens Enveric's position in the neurotherapeutics field.
Read more →ENVBEnveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
Enveric Biosciences has announced the issuance of a new U.S. patent covering a diverse class of novel molecules aimed at treating sleep and central nervous system disorders. The patent enhances the company's intellectual property portfolio and supports its drug discovery platform. The compounds identified may selectively bind to melatonin receptors, indicating potential for innovative therapeutic approaches in psychiatric and neurological indications.
Read more →ENVB▼ -5.5%on this news
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
Enveric Biosciences announced positive preclinical results for its lead drug candidate EB-003, showing significant improvements in a model of severe chronic depression. The study indicated that EB-003 effectively reduced depression-like behavior and had no adverse effects during extended daily dosing. These findings support the compound's potential for treating neuropsychiatric disorders and bolster plans for an Investigational New Drug application.
Read more →ENVBEnveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
Enveric Biosciences has filed a provisional patent for a new group of molecules that may address neurodegenerative diseases by enhancing brain-derived neurotrophic factor (BDNF) activity. Preliminary studies indicate these molecules could promote neuronal development, with potential applications for Alzheimer's disease. However, further testing is necessary to validate these findings.
Read more →ENVB▼ -5.7%on this news
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results
Enveric Biosciences reported its first quarter 2025 financial results, highlighting the unveiling of the EVM401 Series and progress on EB-003, a neuroplastogenic molecule aimed at treating mental health disorders. The company closed a $5 million public offering and aims to submit an IND application for EB-003 by early 2026. Despite a net loss of $2.2 million, Enveric is optimistic about its future in neuroplastogenic therapeutics.
Read more →ENVB▼ -8.1%on this newsshared move
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results Corporate, Business and Product Development Highlights: Unveiled EVM401 Series with new U.S. Patent for mescaline derivative compounds Added
Enveric Biosciences has provided a corporate update detailing progress made in the first quarter of 2025. Significant milestones include the unveiling of the EVM401 Series with a new U.S. Patent and two newly signed licensing agreements for cannabinoid-COX-2 conjugate compounds. The company reported a net loss of $2.2 million, with ongoing efforts to support the filing of an Investigational New Drug application for EB-003 anticipated by the end of Q1 2026. With promising preclinical results, Enveric aims to target difficult mental health disorders, positioning itself for future clinical advancements.
Read more →ENVBThe Future of Psychedelics: Why Next-Generation Molecules Will Win [Microdose]
The psychedelic industry is entering a transformative phase with the emergence of next-generation molecules. These innovative compounds promise to provide effective treatments for various conditions while avoiding the traditional hallucinogenic effects associated with psychedelics. This shift could significantly impact therapeutic approaches and patient outcomes.
Read more →ENVB▼ -5.4%on this newsshared move
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024
Enveric Biosciences reported its financial results for Q4 and the fiscal year ended 2024, highlighting advancements in its lead candidate EB-003, which shows promise for treating severe mental health disorders. The company is preparing to file an IND application to initiate Phase 1 clinical trials. Additionally, Enveric has expanded its pipeline and secured multiple out-licensing agreements, aiming to enhance shareholder value and solidify its position in the neuroplastogen field.
Read more →ENVB▼ -5.4%on this newsshared move
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 Product Development Highlights: Advanced pre-IND and research activities including confirmation of
Enveric Biosciences reported its financial results for Q4 and fiscal year 2024, highlighting advancements in its product development, particularly with EB-003, a potential treatment for severe mental health disorders. The company announced positive preclinical data supporting EB-003's pharmacological safety and efficacy. It also expanded its pipeline through new patents and successfully executed multiple out-licensing agreements. However, Enveric reported a loss of $3.2 million for the quarter, indicating financial challenges ahead as it works towards clinical trials.
Read more →ENVB▼ -5.4%on this news
Enveric Biosciences Participating in BIO-Europe Spring®
Enveric Biosciences is set to participate in BIO-Europe Spring 2025 in Milan, Italy. The company aims to engage with investors and partners to discuss its clinical development strategies and recent achievements. CEO Joseph Tucker highlighted the importance of developing neuroplastogenic molecules, particularly EB-003, for treating mental health disorders without inducing hallucinations.
Read more →ENVB▼ -8.6%on this news· ran to -19% by day 3
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
Enveric Biosciences has initiated a Request-For-Proposals (RFP) process for the licensing or sale of its PsyAI trademark portfolio, which is no longer strategic to its focus on drug development. The company has received interest in the portfolio and aims to maximize its value through this auction process. Enveric's lead compound, EB-003, remains the primary focus as they pivot towards monetizing the PsyAI mark.
Read more →ENVB▼ -7.8%on this news· ran to +22% by day 1
Enveric Biosciences CEO Issues Letter to Shareholders
Enveric Biosciences CEO Joseph Tucker has issued a letter to shareholders outlining the company's strategic focus on EB-003 as its lead product candidate. The company aims to develop EB-003, a non-hallucinogenic neuroplastogen, for treating neuropsychiatric disorders. Enveric has also secured licensing agreements to enhance its portfolio and is preparing for an IND application to advance to Phase 1 clinical trials.
Read more →ENVB▲ +94.9%on this newsshared move
Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds [Microdose]
Enveric Biosciences has obtained its first U.S. patent for the EVM401 Series, a new class of compounds aimed at treating neuropsychiatric disorders. These psychedelic-inspired therapies promise to deliver the advantages of traditional psychedelics while avoiding their hallucinogenic side effects, potentially revolutionizing mental health treatment approaches.
Read more →ENVBEXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD [Benzinga]
Enveric Biosciences has obtained its first U.S. patent for the EVM401 Series, a new set of non-hallucinogenic compounds derived from mescaline. These compounds aim to treat conditions such as addiction and ADHD, providing potential new treatment options for patients with limited alternatives. This development marks a significant step in addressing neuropsychiatric disorders.
Read more →ENVB▼ -13.9%on this news· ran to +104% by day 3shared move
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
Enveric Biosciences has announced the issuance of a U.S. patent for its EVM401 Series of mescaline derivative compounds, aimed at developing neuroplastogen therapeutics for addiction and neuropsychiatric disorders. The patent, issued on January 14, 2025, marks a significant milestone for the company. Preliminary testing suggests these compounds may effectively interact with key neurological receptors, potentially offering new treatment options for patients.
Read more →ENVBA New Horizon in Joint Disease Treatment: Enveric Biosciences and Restoration Biologics Forge Licensing Agreements [Microdose]
Enveric Biosciences has entered into a licensing agreement with Restoration Biologics, enabling the latter to develop and commercialize cannabinoid-COX-2 conjugate compounds. This partnership aims to address joint diseases such as osteoarthritis and rheumatoid arthritis, potentially transforming pain management and regenerative medicine. The agreement covers both pharmaceutical and non-pharmaceutical applications.
Read more →ENVBEnveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease [Benzinga]
Enveric Biosciences, through its subsidiary Akos Biosciences, has signed two licensing agreements with Restoration Biologics. These agreements involve cannabinoid-COX-2 conjugate compounds aimed at treating joint disease. The collaboration suggests a focus on both pharmaceutical and non-pharmaceutical applications.
Read more →ENVBEnveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
Enveric Biosciences has announced two licensing agreements with Restoration Biologics to develop cannabinoid-COX-2 conjugate compounds for treating joint diseases like osteoarthritis and rheumatoid arthritis. Restoration Biologics will have exclusive rights to develop and commercialize these compounds, with potential milestone payments for Enveric totaling up to $82 million. This partnership aims to expand treatment options for patients suffering from joint diseases.
Read more →ENVB▲ +8.4%on this newsshared move
Enveric Biosciences Announces Closing of $5 Million Public Offering
Enveric Biosciences announced the successful closing of a $5 million public offering, which included 1,666,666 shares of common stock and accompanying warrants. The company plans to utilize the proceeds for product development and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Read more →ENVBEnveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
Enveric Biosciences has received a Notice of Allowance from the USPTO for its lead drug candidate EB-003, aimed at treating mental health disorders. The patent covers a novel subset of tryptamine derivatives, which are expected to promote neuroplasticity without inducing hallucinations. This development positions Enveric favorably as it advances EB-003 towards clinical trials.
Read more →ENVB▼ -9.3%on this news· ran to -60% by day 3shared move
Enveric Biosciences Announces Pricing of $5 Million Public Offering
Enveric Biosciences, Inc. announced the pricing of a public offering totaling $5 million, comprising 1,666,666 shares and accompanying warrants. The offering is set to close around February 3, 2025, pending customary closing conditions. Proceeds from the offering are earmarked for ongoing product development and general corporate purposes, highlighting Enveric's commitment to advancing novel therapeutics for mental health issues.
Read more →ENVBEnveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
Enveric Biosciences will present at the Sachs Associates 8th Annual Neuroscience Innovation Forum and participate in the Biotech Showcase 2025 during J.P. Morgan Week 2025. CEO Joseph Tucker will lead discussions on the future of psychedelics and the company's clinical development strategy. The events will facilitate one-on-one meetings with investors to discuss Enveric's achievements and future milestones.
Read more →ENVBEnveric Biosciences Receives Two US Patents for Psilocybin Derivatives [Microdose]
Enveric Biosciences has announced the issuance of two new patents from the US Patent and Trademark Office for its EVM301 and EVM201 series compounds. This development brings the total number of patents for the EVM301 series to 11, highlighting the company's progress in the field of psilocybin derivatives.
Read more →ENVBEnveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
Enveric Biosciences has announced the issuance of two new U.S. patents for its EVM301 series neuroplastogenic molecules, enhancing its intellectual property portfolio. The patents support the development of compounds aimed at treating anxiety, depression, and addiction disorders. Additionally, the company is advancing its lead candidate, EB-003, which has shown promising pre-clinical results. Enveric is also focusing on out-licensing other drug candidates to support its pipeline.
Read more →ENVBEnveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results [Benzinga]
Enveric Biosciences has successfully completed preclinical pharmacokinetic studies for its drug candidate EB-003, which is designed to treat depression and anxiety without inducing hallucinations. This non-hallucinogenic DMT analog shows promise in addressing mental health issues while minimizing side effects associated with traditional psychedelics. The focus on neuroplasticity highlights its innovative approach.
Read more →ENVBEnveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
Enveric Biosciences has completed preclinical pharmacokinetic studies for EB-003, showing dose-proportional oral bioavailability and significant brain penetration in rats. The studies confirmed that EB-003 does not induce hallucination-like behaviors, supporting its potential as a non-hallucinogenic treatment for psychiatric disorders. The company plans to submit an IND application to the FDA in late 2025.
Read more →ENVB▲ +5.2%on this news
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
Enveric Biosciences reported its third quarter 2024 results, highlighting advancements in its lead candidate EB-003, aimed at treating severe mental health disorders. The company confirmed the drug's oral bioavailability and potential for brain penetration. Additionally, it secured out-licensing agreements and expanded its patent portfolio. However, the company reported a net loss of $2.1 million for the quarter.
Read more →ENVBEnveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results Advanced pre-IND activities and research for lead candidate, EB-003, a novel neuroplastogenic molecule designed to treat severe mental health
Enveric Biosciences reported its Q3 2024 financial and corporate results, highlighting advancements in its lead candidate EB-003, designed for treating severe mental health disorders. The company confirmed EB-003's oral bioavailability and favorable preclinical safety results. Enveric also announced significant licensing agreements that are expected to generate non-dilutive revenue. However, the company incurred a loss of $2.1 million in the third quarter and has $3.1 million in cash on hand, which may impact future development efforts.
Read more →ENVB▼ -7.4%on this news· ran to -24% by day 3shared move
Enveric inks $62M licensing deal for psilocin prodrug [Green Market Report]
Enveric Biosciences has entered into a licensing agreement with MycoMedica Life Sciences, potentially worth up to $62 million. This deal grants MycoMedica exclusive global rights to EB-002, a synthetic prodrug of psilocin, aimed at treating neuropsychiatric disorders such as depression. MycoMedica will handle the future development and commercialization of the drug.
Read more →ENVB▼ -7.4%on this news· ran to -24% by day 3shared move
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal [Benzinga]
Enveric Biosciences has licensed its EB-002 drug candidate to MycoMedica Life Sciences, focusing on advancements in mental health treatment. The deal could yield up to $62 million in milestone payments and royalties for Enveric. This allows the company to prioritize its neuroplastogen EB-003 for future development.
Read more →ENVB▼ -7.4%on this news· ran to -24% by day 3shared move
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
Enveric Biosciences has entered a licensing agreement with MycoMedica Life Sciences for its drug candidate EB-002, aimed at treating neuropsychiatric disorders. The agreement includes potential milestone payments of up to $62 million and tiered royalties on future sales. This strategic move allows Enveric to concentrate on advancing its lead candidate, EB-003, while MycoMedica takes on the development of EB-002.
Read more →ENVB▼ -7.4%on this news· ran to -24% by day 3shared move
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 Agreement includes development and sales milestones payments potentially totaling up to $62 million as well as tiered single digi
Enveric Biosciences has signed an out-licensing agreement with MycoMedica Life Sciences for its drug candidate EB-002. Under the agreement, MycoMedica will develop, manufacture, and commercialize EB-002, with Enveric eligible for milestone payments totaling up to $62 million. This strategic decision allows Enveric to concentrate its resources on advancing its lead molecule, EB-003, a novel neuroplastogen targeting neuropsychiatric disorders. MycoMedica will assume all responsibilities for the future development of EB-002.
Read more →ENVB▼ -5.6%on this news
Enveric Biosciences Announces Broad Range of Patent Issuances
Enveric Biosciences has announced the issuance of five new US patents, expanding its EVM301 portfolio of neuroplastogenic compounds. This brings the total to nine patents, enhancing the potential value of its drug candidate library. The lead candidate, EB-003, is in preclinical development for treatment-resistant depression and anxiety, aiming for an IND application in 2025.
Read more →ENVB▼ -5.6%on this newsshared move
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions [Benzinga]
Enveric Biosciences Inc has expanded its intellectual property with the acquisition of five new U.S. patents for its EVM301 portfolio. This increase brings the total number of issued patents to nine, reinforcing the company's commitment to developing neuropsychiatric treatments. The patents pertain to compounds that target mental health conditions through neuroplasticity.
Read more →ENVBEnveric Biosciences Unveils Positive Safety and Pharmacology Data for EB-003 [Microdose]
Enveric Biosciences has released new preclinical data for EB-003, highlighting its ability to effectively target serotonergic receptors while significantly reducing the risks of cardiovascular and CNS side effects. This positions EB-003 as a promising candidate for non-hallucinogenic treatment options for mental health disorders.
Read more →ENVBEnveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
Enveric Biosciences announced positive results from preclinical studies of EB-003, confirming its ability to target specific serotonergic receptors while minimizing adverse cardiovascular and CNS effects. The drug candidate demonstrated a favorable safety profile with no significant off-target interactions. Enveric aims to file an IND application for EB-003 by Q3 2025, with clinical development expected to begin by the end of 2025.
Read more →ENVBPsychedelics 2.0: Companies Explore Safer, More Targeted Therapies [Benzinga]
Enveric Biosciences is exploring a novel approach to psychedelics by developing non-hallucinogenic versions that may act similarly to antidepressants. CEO Joseph Tucker emphasizes that these therapies could offer relief without requiring extensive in-clinic sessions, marking a significant shift in treatment methodologies for mental health.
Read more →ENVB▼ -5.8%on this news
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
Enveric Biosciences presented research on EB-003 at the European Behavioral Pharmacology Society Biennial Workshop. The compound is highlighted for its non-hallucinogenic anxiolytic and anti-depressant properties. The presentation detailed the selection process of EB-003 based on preclinical data, with plans to file an IND application by late 2025.
Read more →ENVBEnveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit [Microdose]
Enveric Biosciences showcased their lead product candidate, EB-003, at the 7th Neuropsychiatric Drug Development Summit. The drug, a non-hallucinogenic analog of DMT, aims to treat anxiety and depression without the hallucinogenic effects. This breakthrough highlights the company's commitment to developing innovative neuroplastogenic therapeutics.
Read more →ENVBEnveric Biosciences Presents Compelling Preclinical Data On Lead Compound EB-003 At 7th Neuropsychiatric Drug Summit [Benzinga]
Enveric Biosciences has announced the presentation of its lead compound, EB-003, at the 7th Neuropsychiatric Drug Summit. EB-003, a non-hallucinogenic DMT analog, demonstrated beneficial effects in preclinical models for anxiety and depression. The summit will take place from September 24-26, 2024, in Boston, MA.
Read more →ENVB▲ +7.1%on this newsshared move
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences’ Breakthrough Research [Benzinga]
Enveric Biosciences has showcased its lead compound, EB-003, at the 7th Neuropsychiatric Drug Summit. This non-hallucinogenic DMT analog demonstrated promising results in preclinical models for treating anxiety and depression. The research highlights the potential of EB-003 as a safer alternative in psychedelic treatments.
Read more →ENVBThis Biotech CEO Is Using Neuroplastogenic Small-Molecule Therapeutics To Create Next Generation Mental Health [Smart Money Podcast]
The article discusses a biotech CEO's efforts to develop neuroplastogenic small-molecule therapeutics aimed at revolutionizing mental health treatment. This innovative approach seeks to address existing challenges in mental health care by creating next-generation solutions. The CEO's leadership and vision are highlighted as key factors in driving this initiative forward.
Read more →ENVBEnveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Enveric Biosciences announced that CEO Joseph Tucker will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024. The presentation will focus on the development of novel neuroplastogenic therapeutics, particularly EB-003, which has shown significant promise in treating depression, anxiety, and addiction. Enveric aims to maximize the value of its assets through its AI-backed drug discovery platform.
Read more →ENVBThe Future Of MDMA-Assisted Therapy After FDA Rejection — Where Do We Go Now? [Clinical Leader]
The FDA's rejection of MDMA-assisted therapy has raised concerns about expectation bias and the complexities of delivering psychological therapy. Joseph Tucker, CEO of Enveric Biosciences, suggests that non-hallucinogenic neuroplastogens could provide therapeutic benefits similar to traditional psychedelics without the regulatory hurdles. This advancement may enhance the acceptance of psychedelic medicine in mainstream healthcare.
Read more →ENVB▼ -7.8%on this newsshared move
FDA Rejects MDMA-Assisted PTSD Therapy [Psychiatrist.com]
The FDA has rejected the MDMA-assisted therapy for PTSD developed by Enveric Biosciences. CEO Joseph Tucker highlighted significant challenges in the study, particularly related to expectation bias and the delivery of psychological therapy. These issues complicate the treatment, especially given the nature of therapies that involve hallucinations. Future therapies may focus on non-hallucinogenic alternatives.
Read more →ENVB▼ -7.8%on this newsshared move
FDA Rejected MDMA-Assisted PTSD Therapy: Psychedelic Industry Responds [Microdose]
The FDA has rejected MDMA-assisted therapy for PTSD, raising concerns about expectation bias and therapy delivery. Dr. Joseph Tucker from Enveric Biosciences noted these challenges and suggested that non-hallucinogenic neuroplastogens could provide therapeutic benefits without the complexities of hallucinogenic experiences. This could represent a significant shift in neuropsychiatric treatment approaches.
Read more →ENVBAries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
Enveric Biosciences and Aries Science & Technology have announced the issuance of a key US patent for a topical product aimed at treating radiation dermatitis. This condition affects around two million cancer patients annually, presenting a substantial market opportunity. The Licensing Agreement allows Enveric to focus on its lead neuroplastogen drug candidate while benefiting from potential milestone payments and royalties from the new product. The partnership aims to enhance treatment options for patients undergoing radiation therapy.
Read more →ENVBEnveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
Enveric Biosciences has prioritized EB-003 as its lead development candidate, a novel neuroplastogenic molecule aimed at treating severe mental health disorders. Recent preclinical results support its oral bioavailability and brain exposure, paving the way for expedited development. The company also reported a net loss of $1.7 million for Q2 2024, while expanding business development efforts to enhance value for stockholders.
Read more →ENVBEnveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results Prioritized EB-003 as lead development candidate. EB-003 is a novel, non-hallucinogenic neuroplastogenic molecule designed to treat severe m
Enveric Biosciences reported its financial and corporate results for the second quarter of 2024, emphasizing the prioritization of EB-003 as its lead development candidate. EB-003 is a novel, non-hallucinogenic molecule designed to treat difficult mental health disorders, showing promising preclinical results. The company plans to file for Investigational New Drug status and begin human trials by the end of 2025. Meanwhile, Enveric also secured licensing agreements and significantly reduced its net losses compared to the previous year, although it ended the quarter with limited cash reserves.
Read more →ENVBEnveric Biosciences Announces Promising Preclinical Results for EB-003 [Microdose]
Enveric Biosciences has reported encouraging preclinical results for its drug candidate EB-003. The findings indicate that EB-003 has good oral bioavailability and significant brain exposure. This positions the drug as a potential treatment for severe neuropsychiatric disorders. The announcement highlights the company's focus on innovative therapies for mental health.
Read more →ENVBNon-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally [Benzinga]
Enveric Biosciences has reported promising preclinical results for its oral drug candidate, EB-003, aimed at treating serious mental health disorders. Unlike traditional psychedelics, EB-003 is designed to be non-hallucinogenic, potentially increasing its safety profile. The drug demonstrated significant brain exposure in rodent models, suggesting its therapeutic potential.
Read more →ENVBEnveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
Enveric Biosciences announced positive preclinical results for EB-003, indicating its potential for oral administration and significant brain exposure. The drug aims to treat severe mental health disorders without the hallucinogenic effects associated with traditional psychedelics. The company plans to file an IND application by 2025 and begin clinical trials by the end of that year.
Read more →ENVBAries Science & Technology and Enveric Biosciences Announce Licensing Agreement
Enveric Biosciences has entered into a licensing agreement with Aries Science & Technology to develop a topical product for radiation dermatitis. This condition affects approximately two million cancer patients annually, presenting a market opportunity of $400 million. The partnership aims to leverage Aries' expertise in encapsulation to advance the product through clinical trials, with potential milestone payments of up to $61 million for Enveric.
Read more →ENVBAries Science & Technology and Enveric Biosciences Announce Licensing Agreement Aries to clinically develop and market Enveric's patented product for radiation dermatitis
Enveric Biosciences has entered into a licensing agreement with Aries Science & Technology to clinically develop and market a topical product for radiation dermatitis, which affects approximately two million cancer patients annually. The agreement allows Enveric to potentially receive up to $61 million in milestone payments, alongside royalties on future sales. This partnership aims to leverage Aries's expertise in encapsulation technologies to advance the product toward clinical trials. Both companies expressed enthusiasm regarding the venture, highlighting the unmet needs of cancer patients facing painful side effects from radiation therapy.
Read more →ENVB▲ +5.8%on this news· ran to +19% by day 3shared move
Enveric Biosciences Announces Patent Granted for Drug Candidate
Enveric Biosciences has announced the issuance of a new US patent for its drug candidate EB-002, which expands its intellectual property protection for treating various brain neurological disorders. The patent covers methods of treatment for conditions such as sleep disorders, depression, and substance-related disorders. This development is expected to enhance the potential of EB-002 in clinical applications.
Read more →ENVB▼ -7.3%on this news
BUSINESSPUBLIC Enveric bets on trip-free mental health drug for FDA approval hopes [Green Market Report]
Enveric Biosciences is prioritizing the development of EB-003, a new compound aimed at treating mental health disorders without causing hallucinations. The drug is designed to enhance neuroplasticity, distinguishing it from traditional psychedelic treatments. The company plans to hold a pre-IND meeting with the FDA in early 2025 to discuss its progress.
Read more →ENVB▼ -7.3%on this newsshared move
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
Enveric Biosciences has elevated EB-003 as its lead candidate for treating severe mental health disorders. This novel neuroplastogenic molecule aims to promote neuroplasticity without the hallucinogenic effects associated with traditional psychedelics. The company is advancing pre-clinical development and plans a Pre-IND meeting with the FDA for early 2025.
Read more →ENVBPsychedelic Community Reacts To FDA Committee’s Critique Of Lykos’ MDMA Studies [Clinical Leader]
An FDA advisory committee voted 9-2 against the validity of Lykos Therapeutics' MDMA clinical trials for PTSD. The committee's concerns centered on expectation bias and the delivery of psychological therapy. Industry leaders, including Joseph Tucker of Enveric Biosciences, expressed that these issues may not apply to upcoming non-hallucinogenic neuroplastogens, which could dominate neuropsychiatric treatments.
Read more →ENVBPsychedelics companies see FDA panel’s vote as a growth opportunity, not a roadblock [Stat News]
Following an FDA panel's concerns regarding MDMA for PTSD treatment, psychedelics companies remain optimistic. They view the panel's feedback as a constructive guide for future drug approvals. This perspective highlights the potential for growth in the psychedelics sector despite regulatory challenges.
Read more →ENVBEnveric Biosciences to Participate in BIO International Convention 2024
Enveric Biosciences will participate in the 2024 BIO International Convention in San Diego from June 3-6. The management team aims to engage with potential investment and development partners to discuss collaborations for their promising drug candidates. CEO Joseph Tucker expressed optimism about the interest from strategic partners in their drug discovery assets.
Read more →ENVBEnveric, MindBio partner to advance psilocin prodrugs for mental health disorders [Healio]
Enveric Biosciences has entered into a nonbinding term sheet to out-license novel psilocin prodrugs to MindBio Therapeutics. This partnership is expected to potentially generate over $66 million in sales, indicating a strong market interest in mental health disorder treatments.
Read more →ENVBRx Rundown: Sanofi, Bayer, Sands Capital and more [MMM]
Enveric Biosciences has entered into a non-binding term sheet to out-license a class of novel psilocin products to MinBio Therapeutics. This agreement could yield up to $66.5 million in milestone payments, marking a significant step for the development-stage company. The deal may bolster Enveric's pipeline and investor interest.
Read more →ENVB▲ +9.9%on this newsshared move
‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand [Benzinga]
Enveric Biosciences announced its financial results for Q1 2024, highlighting a productive period focused on the development of EB-003, a neuroplastogen drug candidate. CEO Joseph Tucker emphasized the drug's potential to improve safety profiles in treating neuropsychiatric conditions. The company also reported a reduction in net loss year-over-year and an increase in cash reserves.
Read more →ENVB▲ +10.5%on this newsshared move
Major deals continue positive trajectory for psychedelics in 2024 [Psychedelic Health]
The psychedelics market is experiencing significant growth in 2024, highlighted by major developments such as AbbVie's entry into the sector and a substantial $66.5 million deal between Enveric and MindBio. These events indicate a positive trajectory for innovative medicines in this field as the year unfolds.
Read more →ENVB$6M bankrolls Enveric pipeline partnering, depression program [Green Market Report]
Enveric Biosciences has announced a partnership with MindBio and is pursuing licensing contracts for its pipeline candidates. The company reported a net loss of $2.46 million for Q1 2024 but raised $4.5 million through equity issuances. Enveric is focusing on advancing its lead non-hallucinogenic asset.
Read more →ENVBPsychedelics for Depression: MindBio and Enveric’s Joint Efforts [TDR]
MindBio Therapeutics and Enveric Biosciences are collaborating to develop treatments for neuropsychiatric disorders using microdosing psychedelics. Their efforts focus on novel psilocin prodrug candidates, aiming to provide mental health solutions without the hallucinogenic effects typically associated with psychedelics. This partnership marks a significant step in the field of psychedelic medicine.
Read more →ENVBEnveric Biosciences to out-license psilocin prodrug to MindBio [Pharmaceutical Technology]
Enveric Biosciences has signed a non-binding term sheet with MindBio Therapeutics to out-license a class of psilocin prodrugs. These prodrugs are designed to treat mental health disorders by metabolizing and releasing therapeutic levels of psilocin at varying rates. This collaboration could enhance treatment options in mental health.
Read more →ENVBEnveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
Enveric Biosciences reported strong progress in Q1 2024, unveiling seven classes of novel drug candidates and advancing its lead candidate, EB-003, towards an IND filing and Phase 1 trial. The company executed seven non-binding term sheets with strategic partners, potentially worth $410 million in milestone payments. However, it also reported a net loss of $2.46 million for the quarter.
Read more →ENVBEnveric Biosciences Reports First Quarter 2024 Financial and Corporate Results Revealed seven classes of promising novel drug candidates discovered using Enveric's Psybrary and PsyAI drug discovery and artificial intelli
Enveric Biosciences has announced its financial and corporate results for Q1 2024, highlighting the discovery of seven classes of drug candidates leveraging AI technology. The company executed seven non-binding term sheets with four strategic partners, potentially translating to significant milestone payments and future royalties. Advancements were made on their lead drug candidate, EB-003, aimed at treating neuropsychiatric disorders without inducing hallucinations, with preparations underway for an IND application and Phase 1 trial. Financially, they reported a loss compared to the previous year, but retained optimism due to incoming partnerships.
Read more →ENVBEnveric signs deal with MindBio [Green Market Rerport]
Enveric Biosciences has entered into a non-binding term sheet to out-license its Novel Psilocin Prodrugs to MindBio Therapeutics. This partnership aims to advance treatments for psychiatric conditions through the use of microdoses of psychedelic medicines. MindBio is recognized for its innovative approach in the biopharma sector.
Read more →ENVBAdvancing Mental Health Treatments: The Strategic Collaboration Between Enveric Biosciences and MindBio Therapeutics [Microdose]
Enveric Biosciences has announced a collaboration with MindBio Therapeutics to develop innovative treatments for mental health disorders. This partnership focuses on utilizing microdoses of psychedelic medicines to address conditions such as depression, anxiety, and addiction. The collaboration is expected to enhance the development of neuroplastogenic therapies.
Read more →ENVBEnveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders [Psychedelic Invest]
Enveric Biosciences has entered into a non-binding term sheet to out-license its Novel Psilocin Prodrugs to MindBio Therapeutics. This collaboration aims to develop treatments for mental health disorders, including depression and anxiety. The partnership highlights Enveric's commitment to innovative therapeutic solutions in the psychedelic medicine sector.
Read more →ENVBMicrodosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate [Benzinga]
Enveric Biosciences has signed a non-binding term sheet to out-license its Novel Psilocin Prodrugs to MindBio Therapeutics, which focuses on microdosing for psychiatric conditions. This deal follows another non-binding agreement for cancer treatment methods. The collaboration signifies a growing trend in psychedelic research for mental health.
Read more →ENVB▲ +7.2%on this news
A Pioneering Push in Cancer Treatment: Enveric Biosciences Advances with Cannabinoid Therapies [Microdose]
Enveric Biosciences has announced a licensing agreement to explore cannabinoid therapies in cancer treatment. This agreement, signed with an undisclosed licensee, focuses on integrating cannabinoids with chemotherapeutic drugs, particularly for breast cancer. The initiative represents a promising advancement in the field of oncology.
Read more →ENVB▲ +10.1%on this newsshared move
Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods [Benzinga]
Enveric Biosciences has signed a non-binding term sheet for an exclusive license with an undisclosed biotech company. This deal involves two patented methods that combine cannabinoids with chemotherapy to treat breast cancer and other cancers. The financial terms of the agreement are valued at $61 million.
Read more →ENVB▲ +10.1%on this newsshared move
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
Enveric Biosciences has signed a non-binding term sheet with an undisclosed licensee for exclusive rights to patented methods for treating breast cancer and other cancers using cannabinoids combined with chemotherapeutic drugs. This agreement could lead to significant financial milestones and supports the advancement of cannabinoid-based treatments, especially following recent regulatory changes regarding marijuana. The licensed methods are expected to progress into preclinical and clinical development stages.
Read more →ENVBRethinking Mental Health: How Emerging Therapies Are Changing the Game [Newsweek]
The article discusses the ongoing challenges in treating mental health disorders globally, emphasizing the inadequacies of current therapies. It highlights the emergence of several companies focused on developing innovative treatments that could significantly improve mental health care. The need for groundbreaking solutions in this field is underscored by the substantial burden these disorders place on healthcare systems.
Read more →ENVBUnlocking New Horizons: Enveric Biosciences’ Strategic Moves in Biotechnology [Microdose]
Enveric Biosciences has signed two non-binding term sheets with an undisclosed biotechnology company to advance joint disease treatment. This collaboration aims to utilize cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications. The initiative reflects Enveric's commitment to innovation in medical biotechnology.
Read more →ENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
Enveric Biosciences reported its financial results for Q4 2023 and highlighted significant advancements in its drug development pipeline. The company selected EB-003 as its lead candidate for treating mental health disorders, while also progressing preclinical work for EB-002. Enveric signed multiple non-binding term sheets for out-licensing agreements and expanded its intellectual property portfolio with several new patents.
Read more →ENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-i
Enveric Biosciences reported its financial results for the fourth quarter and fiscal year 2023, highlighting the selection of EB-003 as its lead therapeutic candidate for challenging mental health disorders. The company has initiated preclinical activities for both EB-003 and EB-002, with the latter nearing Phase 1 readiness. Enveric also secured multiple non-binding term sheets for out-licensing opportunities, reflecting growing interest in its innovative compounds. However, the company faced a financial loss in the last quarter, despite a decrease in its loss per share compared to the previous year.
Read more →ENVB▲ +8.2%on this news
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease Second biotechnology company to pot
Enveric Biosciences (NASDAQ: ENVB) has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the exclusive out-licensing of cannabinoid-COX-2 conjugate compounds for joint disease applications. These agreements could result in milestone payments up to $82 million, dependent on meeting various development and sales criteria. The respective licensee would take on product development responsibilities, allowing Enveric to potentially benefit from a steady revenue stream. The partnership marks a significant step in advancing treatment options for joint diseases.
Read more →ENVBFrom LSD to healing minds: Where are we standing in psychedelic drug development? [Labiotech]
The article discusses the evolving perception of mental health conditions and psychedelic substances. It highlights the progress made in psychedelic drug development, which is gaining financial viability and societal acceptance. The stigma surrounding both mental illness and psychedelics is gradually diminishing, reflecting a significant shift in public and scientific attitudes.
Read more →ENVBEnveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
Enveric Biosciences announced the issuance of two new patents that protect various proprietary compounds aimed at treating mental health disorders. The patents enhance the company's intellectual property portfolio and highlight opportunities for licensing agreements. Enveric continues to advance its lead programs while inviting collaboration with partners in drug development.
Read more →ENVB▲ +74.5%on this news
Avidity to raise $400M; Sato pays Arcutis $25M upfront to license topical roflumilast in Japan [Endpoints News]
Avidity is set to raise $400 million, reflecting robust investor interest. Additionally, Sato has made a $25 million upfront payment to Arcutis for the licensing of topical roflumilast in Japan, which may broaden the market for this treatment. The article also mentions updates on several other biopharma companies.
Read more →ENVB▲ +74.5%on this newsshared move
Dr. Joe Tucker, CEO of Enveric Biosciences [The Green Rush]
Dr. Joseph Tucker, CEO of Enveric Biosciences, discusses the company's advancements in neuroplastogen therapeutics, particularly highlighting EB-003 as the lead candidate in the EVM 301 series. The conversation also provides insights for retail investors interested in drug discovery within the neuropsychiatric space.
Read more →ENVB▲ +74.5%on this newsshared move
12 Health Care Stocks Moving In Thursday’s Pre-Market Session [Benzinga]
Enveric Biosciences experienced a significant stock increase of 162.3%, reaching a price of $2.18 during Thursday's pre-market session. The company's current market capitalization stands at $5.9 million. Despite this rise, Enveric remains a development stage company with no marketed products.
Read more →ENVB▲ +74.5%on this newsshared move
EXCLUSIVE: Enveric Biosciences Announces Non-Binding Deals To License Out Three Types of Drug Compounds [Benzinga]
Enveric Biosciences has entered into three non-binding term sheets with an undisclosed biotechnology company to license out three classes of drug compounds. This move aims to enhance their portfolio of neuroplasticity-promoting therapeutics for treating depression, anxiety, and addiction disorders. The agreements signify a strategic expansion for the company.
Read more →ENVB▲ +74.5%on this newsshared move
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
Enveric Biosciences has signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds. These agreements could lead to significant milestone payments totaling up to $200 million, contingent on meeting specific development and sales criteria. The compounds are sourced from Enveric's extensive library created through its proprietary drug discovery platforms.
Read more →ENVB▲ +74.5%on this newsshared move
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds Potentially significant milestone payments and execution fees if all development and sales criteria ar
Enveric Biosciences has signed three non-binding term sheets to pursue the exclusive out-licensing of three classes of compounds aimed at treating mental health conditions. This partnership may lead to milestone payments and execution fees totaling up to $200 million, contingent upon meeting certain development criteria. The compounds originate from Enveric's extensive library and their proprietary Psybrary platform. However, since these agreements are non-binding, their successful progression into definitive agreements remains uncertain.
Read more →ENVBEnveric Biosciences Sells Cancer Patents As It Paves Way For Mental Health Treatments [Benzinga]
Enveric Biosciences Inc. has announced the sale of its cancer-related patent portfolio, although the financial details of the transaction remain undisclosed. The portfolio includes patents issued in several countries, including the U.S., Australia, and Europe, along with pending applications in Canada, Israel, and Korea. This strategic move is aimed at reallocating resources towards mental health treatments.
Read more →ENVB▲ +15.3%on this newsshared move
Enveric sells cannabis patents to focus on psilocin candidates [Green Market Report]
Enveric Biosciences is selling its cancer-related patent portfolio to concentrate on developing its lead candidates, EB-003 and EB-002. EB-003 is a neuroplastogen aimed at eliminating hallucinations, while EB-002 is a synthetic prodrug of psilocin. This strategic shift reflects Enveric's commitment to advancing its innovative therapies.
Read more →ENVB▲ +15.3%on this newsshared move
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
Enveric Biosciences has agreed to sell a cancer-related patent portfolio to focus on its lead neuroplastogenic candidates, EB-003 and EB-002. The divested portfolio includes patents for the combination of cannabidiol and other therapeutic agents for cancer treatment. This strategic move is intended to enhance Enveric's investment in mental health disorder treatments while providing foundational patent protection for the new owners.
Read more →ENVBEnveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compounds [Benzinga]
Enveric Biosciences has announced the discovery of several new compounds through its Psybrary platform, utilizing advanced computational chemistry and AI. These compounds represent seven distinct molecule classes, providing at least 57 unique product opportunities. The innovations are safeguarded by Enveric's extensive intellectual property portfolio.
Read more →ENVBEnveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
Enveric Biosciences has announced the discovery of a library of novel preclinical compounds aimed at treating mental health disorders, utilizing its Psybrary and PsyAI platforms. The compounds span seven distinct molecule classes, offering at least 57 unique product opportunities. This expansion is expected to enhance Enveric's intellectual property portfolio and create potential licensing revenue.
Read more →ENVBEnveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders Novel compounds protected under Enveric's intellectual property portfolio provide p
Enveric Biosciences has announced the creation of a robust library of preclinical compounds aimed at treating mental health disorders, utilizing its Psybrary and PsyAI platforms. The new compounds span seven distinct molecule classes, offering at least 57 unique product opportunities. This development is expected to enhance the company's intellectual property portfolio and facilitate potential licensing opportunities, positioning Enveric as a key player in neuroplastogenic small-molecule therapeutics. Lead candidates include EB-003, designed to eliminate hallucinations, and EB-002, a synthetic prodrug of psilocin.
Read more →ENVB▲ +5.1%on this news
Non-Hallucinogenic Psilocybin-Based Therapies Promote Neuroplasticity Show Promise Treating Mental Health Disorders with Joe Tucker Enveric Biosciences [Empowered Patient Podcast]
Joe Tucker, CEO of Enveric Biosciences, highlights the potential of neuroplastogen therapies for treating neuropsychiatric disorders such as depression and PTSD. The company's Psybrary portfolio features compounds inspired by psilocybin that promote neuroplasticity without causing hallucinations. The lead candidate, EB-003, is designed for regular oral administration as a maintenance therapy.
Read more →ENVBNovel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders [ACS Publications]
Researchers have developed novel psilocin prodrugs aimed at treating treatment-resistant anxiety disorders. These prodrugs maintain the therapeutic benefits of psilocybin while reducing the duration of its psychedelic effects. The study involved synthesizing 28 new chemical entities to achieve altered pharmacokinetic profiles, potentially improving the application of psilocybin therapy.
Read more →ENVBThe trends that will shape the biotech industry in 2024 [Labiotech]
The biotechnology industry is expected to recover in 2024, driven by technological advancements and favorable market conditions. A recent PwC report forecasts M&A activity to significantly impact the market, with deal totals projected between $225 billion and $275 billion. This trend is anticipated to reshape the biotech landscape.
Read more →ENVB30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond [Benzinga]
The psychedelics industry is rapidly expanding, with substances like psilocybin and MDMA showing potential for treating mental health issues. The global market for psychedelic drugs was valued at $2.6 billion in 2022 and is projected to grow to $7.1 billion by 2032, indicating a strong compound annual growth rate of 10.9%.
Read more →ENVBEnveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
Enveric Biosciences has selected EB-003 as its lead drug candidate from the EVM301 Series, aiming to treat depression, anxiety, and addiction disorders. The selection is based on promising data indicating EB-003's potential as a first-in-class neuroplastogenic molecule. The company plans to begin preclinical development in 2024 to prepare for an IND submission.
Read more →ENVBEnveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission
Enveric Biosciences has announced the selection of EB-003 as its lead drug candidate from the EVM301 series, with plans to initiate preclinical development in 2024. The decision is based on new data indicating the drug's potential effectiveness in treating challenging mental health disorders while minimizing the likelihood of hallucinations. The company aims to file an IND and start clinical trials following these preliminary studies. Enveric utilizes an advanced AI-driven drug discovery platform to select promising drug candidates and create a robust portfolio of neuroplastogenic therapeutics.
Read more →ENVBEnveric’s EB-003 selected as lead candidate for mental health disorders [Pharmaceutical Technology]
Enveric Biosciences has chosen EB-003 as its lead candidate for treating challenging mental health disorders. This decision follows data assessments that highlight EB-003's potential to be a first-in-class treatment. The drug is designed to enhance neuroplasticity while avoiding hallucinations, marking a significant advancement in mental health therapies.
Read more →ENVBEnveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
Enveric Biosciences announced a private placement generating approximately $1.8 million in gross proceeds through the exercise of existing warrants. Current warrant holders will exercise these warrants at a reduced price, receiving new warrants in exchange. The company is focused on developing novel therapeutics for various mental health disorders. However, the success of its programs depends on several uncertain factors, including clinical trials and regulatory approvals.
Read more →ENVBEnveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
Enveric Biosciences has selected EB-003 as its lead drug candidate from the EVM301 Series, aimed at treating depression, anxiety, and addiction disorders. The decision was based on promising data indicating EB-003's potential to promote neuroplasticity without causing hallucinations. Preclinical development is set to begin in early 2024 in preparation for an IND submission for clinical trials.
Read more →ENVBEnveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission
Enveric Biosciences has chosen EB-003 as its lead drug candidate from the EVM301 series, aimed at treating difficult mental health disorders. The selection is based on its potential for promoting neuroplasticity without inducing hallucinogenic effects. The company plans to start preclinical development of EB-003 in early 2024, preparing for an Investigational New Drug application. This decision signifies a key transition for Enveric from a discovery-focused company to a drug development entity.
Read more →ENVBEnveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
Enveric Biosciences reported positive progress in the preclinical development of EB-373, a novel psilocin prodrug. The ongoing GLP Safety and Toxicology Program is on track, with favorable results from various safety studies. The company anticipates finalizing preclinical activities by Q1 2024, paving the way for first-in-human trials.
Read more →ENVBEnveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 The ongoing GLP Safety and Toxicology Program of EB-373 is thus far proceeding on time with favorable results
Enveric Biosciences has reported significant progress in the preclinical development of its lead prodrug candidate, EB-373, which is focused on treating depression, anxiety, and addiction disorders. The ongoing GLP Safety and Toxicology Program is showing favorable results, with key studies completed and overall safety profiles indicating a wide margin of safety. The company is on track to finalize preclinical activities by Q1 2024 in preparation for human trials. The updates reflect the commitment of Enveric to advance novel therapeutics based on its AI-backed molecular design.
Read more →ENVBEnveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
Enveric Biosciences will participate in the Biotech Showcase 2024 from January 8-10 in San Francisco. The event will allow the management team to meet with investors and partners, highlighting the company's clinical development strategies and recent achievements. Enveric focuses on developing novel therapeutics for mental health disorders using its Psybrary™ platform.
Read more →ENVBTrip Or No Trip Pharmas Are Taking Psychedelic Trials To Australia [Clinical Leader]
Enveric Biosciences is advancing its psychedelic therapies, focusing on regulatory approval in Australia. CEO Joseph Tucker discusses the company's pipeline, which includes hallucinogenic and non-hallucinogenic treatments for mental health disorders. The leading candidate, EB-373, is set for a Phase 1 clinical trial in early 2024.
Read more →ENVBThe Path to Regulation of Psychedelic Therapies with Dr. Joe Tucker Enveric Biosciences [Digital Politics with Karen Jagoda]
The Digital Politics Podcast features Karen Jagoda discussing the influence of technology on political campaigns. It covers voter expectations, online fundraising, and methods of persuasion. The episode includes insights from Dr. Joe Tucker of Enveric Biosciences regarding the regulation of psychedelic therapies.
Read more →ENVBEnveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
Enveric Biosciences has identified three novel compounds from its EVM301 Series aimed at treating depression, anxiety, and addiction without inducing hallucinations. The company plans to select one candidate for expedited preclinical development in 2024, with an Investigational New Drug application anticipated for a first-in-human trial. The compounds show promise in promoting neuroplasticity and have favorable pharmacokinetic profiles.
Read more →ENVBEnveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds Three novel neuroplastic compounds identified w
Enveric Biosciences has selected three novel compounds from its EVM301 Series that aim to minimize or eliminate the hallucinogenic effects of psychedelic-derived treatments. These compounds promote neuroplasticity and show promise in treating difficult mental health disorders such as depression and anxiety. Enveric plans to advance one candidate into preclinical development in 2024 with hopes of submitting an Investigational New Drug application for first-in-human trials. This selection marks a significant step forward in the company’s drug development efforts in the mental health field.
Read more →ENVBEnveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
Enveric Biosciences has received a Notice of Allowance from the USPTO for its EVM301 Series, which includes glycosylated psilocybin derivatives aimed at treating mental health disorders. The patent covers both composition of matter and methods of use, enhancing the company's intellectual property portfolio. The compounds are designed to promote neuroplasticity without causing hallucinations, potentially changing treatment paradigms for depression and anxiety.
Read more →ENVBEnveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives Expands intellectual property portfolio with composition of matter and methods of use claims governing En
Enveric Biosciences has received a Notice of Allowance from the USPTO for its EVM301 Series, which includes glycosylated psilocybin derivatives. This patent approval adds to the company's intellectual property for novel therapeutic molecules aimed at treating depression and anxiety without inducing hallucinations. Enveric believes this development may revolutionize treatment for mental health disorders and improve commercial prospects for its drug candidates. Multiple compositions of matter patent applications have also been filed, increasing their market competitiveness.
Read more →ENVBEnveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
Enveric Biosciences announced that its lead product candidate, EB-373, will be featured on the cover of the Journal of Medicinal Chemistry. The article details the development of a library of novel psilocin prodrugs aimed at treating anxiety disorders. The company is advancing EB-373 through preclinical studies, expecting to complete them by the end of 2023.
Read more →ENVBEnveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)
Enveric Biosciences announced the presentation of two posters at the Canadian Chemical Engineering Conference (CSChE 2023). The first poster detailed a biocatalytic method for producing MDMA, while the second introduced a synthetic biology platform for creating novel drug candidates for anxiety and depression. Both presentations emphasized the advantages of metabolic engineering in drug development.
Read more →ENVBEnveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results
Enveric Biosciences reported its third quarter 2023 results, highlighting advancements in its neuroplastogenic drug candidates, particularly the EVM301 Series and EB-373. The company has strengthened its intellectual property with new patents and reported positive preclinical results for EB-373. Despite a net loss of $2.82 million, Enveric is optimistic about upcoming milestones, including the identification of a lead candidate by year-end.
Read more →ENVBEnveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results EVM-301 Series Presented and published leading scientific research describing development and screening methods for non-hallucinogenic, neuro
Enveric Biosciences provided a corporate update and financial results for the third quarter of 2023, highlighting significant advancements in their EVM301 Series and AI-powered drug discovery initiatives. The company reported advancements in preclinical safety studies for their lead candidate, EB-373, alongside recent patent grants enhancing their intellectual property. Financial results included a net loss of $2.82 million, which was a slight increase from the prior year. Enveric is poised for future growth with an anticipated lead candidate identification by year-end 2023.
Read more →ENVBJoseph Tucker – Drugs for Neuroplasticity [The Mindfulness Experience Podcast]
In a recent episode of The Mindfulness Experience Podcast, host Keith Fiveson interviews Dr. Joseph Tucker, CEO of Enveric Biosciences. The discussion centers on the company's commitment to developing small-molecule therapeutics aimed at treating anxiety, depression, and addiction disorders. Dr. Tucker's extensive experience in biotechnology is emphasized as a key asset in their mission.
Read more →ENVBPsilocin prodrug receives USPTO development approval [Psychedelic Health]
Enveric Biosciences has secured a Notice of Allowance from the USPTO for its patent application related to EB-373, a prodrug of psilocin. This development marks a significant step for the company in the psychedelic health sector. The approval may strengthen Enveric's market position and innovation in this emerging field.
Read more →ENVBEnveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin
Enveric Biosciences has received a Notice of Allowance from the USPTO for its lead candidate, EB-373, a psilocin prodrug aimed at treating depression and anxiety. The patent includes composition of matter claims for novel derivatives, bolstering Enveric's intellectual property portfolio. The company anticipates clinical trials to assess EB-373's effectiveness and safety compared to conventional treatments.
Read more →ENVBEnveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin Expands its intellectual property portfolio with compositi
Enveric Biosciences has announced the receipt of a Notice of Allowance from the USPTO for a patent application related to EB-373, a psilocin prodrug intended for treating depression and anxiety disorders. This patent strengthens Enveric's intellectual property portfolio, positioning the company favorably for its clinical endeavors. Additionally, Enveric aims to bring EB-373 to clinical trials soon, with expectations for improved efficacy and safety over existing treatments. The company is advancing its innovative formulations through multiple patent filings, further solidifying its research capabilities.
Read more →ENVBEnveric Biosciences to Present at the Centurion One 5th Global Summit
Enveric Biosciences will present at the Centurion One 5th Global Summit on October 25, 2023. CEO Joseph Tucker will lead a company presentation and participate in a panel discussion. The summit will provide a platform for Enveric to showcase its business strategy and clinical developments to potential investors.
Read more →ENVBEnveric Biosciences to Present at the Centurion One 5 th Global Summit CEO Joseph Tucker, Ph.D., to deliver company presentation and participate in panel discussion
Enveric Biosciences announced that CEO Joseph Tucker, Ph.D., will present at the Centurion One 5th Global Summit on October 25, 2023, in Nassau, Bahamas. The summit provides a platform for Enveric to showcase its development strategies, recent achievements, and upcoming milestones. The company is focused on novel neuroplastogenic therapeutics aimed at mental health conditions such as depression and addiction disorders. Attendees will include prominent investors from various sectors, indicating significant interest in Enveric's innovative approaches.
Read more →ENVBAligning financial plans to long-term goals [The CFO]
Kevin Coveney, CFO of Enveric Biosciences, highlights the importance of the CFO's role in supporting the CEO to achieve long-term financial goals. He emphasizes the need for CFOs to understand the business's nature and background to effectively contribute to leadership and strategic planning.
Read more →ENVBEnveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders
Enveric Biosciences has commenced Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for its lead candidate EB-373, a psilocin prodrug aimed at treating psychiatric disorders. These studies are crucial for establishing the safety profile and maximum tolerated dose required for upcoming clinical trials. Previous non-GLP studies indicated a favorable safety profile, supporting the potential for EB-373 in therapeutic applications.
Read more →ENVBEnveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders Key preclinical milestone designed to establish saf
Enveric Biosciences has announced the initiation of Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for its lead candidate, EB-373, which is a next-generation psilocin prodrug aimed at treating psychiatric disorders. This step is significant as it aims to establish the safety profile and maximum tolerated dose necessary for clinical trials. Previous non-GLP studies indicated a favorable safety profile, and the ongoing GLP studies are expected to further validate these findings, potentially expanding the therapeutic applications of EB-373.
Read more →ENVBEnveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit
Enveric Biosciences announced two poster presentations at the 6th Neuropsychiatric Drug Development Summit. The presentations focus on the EVM301 Series of non-hallucinogenic neuroplastogens and the lead candidate EB-373, a novel prodrug of psilocin. The research highlights the company's innovative approach to treating anxiety, depression, and addiction disorders.
Read more →ENVBEnveric Biosciences Announces Two Poster Presentations at the 6 th Neuropsychiatric Drug Development Summit Presentations highlight research involving Enveric's EVM301 Series of non-hallucinogenic neuroplastogens and the
Enveric Biosciences announced two poster presentations at the 6th Neuropsychiatric Drug Development Summit, focusing on its EVM301 Series of non-hallucinogenic neuroplastogens. The presentations highlight the selection of a lead candidate from over 50 tested molecules and the advancement of EB-373, a psilocin prodrug, through preclinical development. These findings showcase Enveric's commitment to creating novel therapies for mental health conditions without the side effects associated with traditional psychoactive compounds.
Read more →ENVBHas British biotech outgrown the Square Mile? [Proactive]
The article discusses Britain's strengths in biotech innovation, particularly due to the Golden Triangle. However, it highlights the challenges faced in nurturing these innovations to reach blue-chip status, attributing this to the conservative nature of the British investment class.
Read more →ENVBEnveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
Enveric Biosciences has announced that its Psybrary™ portfolio now includes over 1000 psychedelic-inspired therapeutic candidates. This milestone highlights the company's innovative AI-driven drug discovery platform, PsyAI™, which facilitates the design of new compounds for mental health treatment. The portfolio aims to address significant mental health disorders, including treatment-resistant depression and anxiety, with a lead candidate expected to be nominated in early 2024.
Read more →ENVBEnveric Biosciences Announces its Psybrary Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates The Psybrary portfolio includes numerous unique, previously unreported molecules, which are protected
Enveric Biosciences has announced that its Psybrary portfolio now includes over 1000 psychedelic-inspired therapeutic candidates. This milestone is attributed to the company's proprietary AI drug-discovery platform, PsyAI, which aids in the rapid design and synthesis of new compounds. The firm is focusing on developing treatments for mental health conditions such as treatment-resistant depression and anxiety, leveraging the diverse structures in its portfolio. Enveric is also open to collaborations to expedite the availability of these new therapies to patients.
Read more →ENVBBiotech firm receives patent for psilocybin-derived mental health therapeutics [Helio]
A biotechnology firm based in the Boston area has secured a patent for its EVM301 series of psilocybin-derived molecules. This patent, titled 'Carboxylated Psilocybin Derivatives and Methods of Using,' is aimed at treating various mental health disorders. The development marks a significant step in the firm's efforts to innovate in mental health therapeutics.
Read more →ENVBPsilocybin-Based Drug Candidate Gains Patent [High Times]
Enveric Biosciences has successfully obtained a patent for its psilocybin-based drug candidate. This strategic move places the company ahead of competitors in the burgeoning psychedelic market. The growing interest in psychedelics within the medical community further enhances the significance of this patent.
Read more →ENVBEnveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
Enveric Biosciences has published a paper detailing the discovery of a novel enzyme, Rhinella marina N-methyltransferase, from the cane toad. This enzyme facilitates the biosynthesis of new indolethylamine-type drug candidates, potentially useful in treating psychiatric conditions. The research highlights Enveric's innovative bioproduction platform and its commitment to developing novel therapeutics for mental health disorders.
Read more →ENVBEnveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry Paper co-authored by Enveric researchers descr
Enveric Biosciences has announced the publication of a paper in the Journal of Biological Chemistry detailing the discovery of a new enzyme from the cane toad that can aid in synthesizing novel drug candidates for psychiatric medicine. This research represents a significant advancement in the company's efforts to develop neuroplastogenic therapeutics targeting depression, anxiety, and addiction disorders. The enzyme, Rhinella marina N-methyltransferase (RmNMT), exhibits unique properties that enhance its suitability for producing psychedelic-inspired compounds. This work continues to bolster Enveric's capabilities in innovative drug discovery through its bio-based production systems.
Read more →ENVBU.S. approval for psychedelic drug MDMA nears after success in clinic [Labiotech]
The psychedelic drug MDMA is approaching FDA approval for PTSD treatment following successful clinical trial results. This development follows Australia's pioneering decision to allow prescriptions of MDMA for mental health disorders, including PTSD and depression. The advancements signal a significant shift in the acceptance of psychedelic treatments in mental health care.
Read more →ENVBEnveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here [Benzinga]
Enveric Biosciences has been granted a new patent by the U.S. Patent and Trademark Office for its psilocybin-based molecules, specifically the EVM301 series. This patent includes rights to the novel composition of matter and methods of use, potentially strengthening the company's position in the biopharma sector.
Read more →ENVBEnveric Receives Patent For Psilocybin Molecules [Green Market Report]
Enveric Biosciences has been granted U.S. Patent No. 11,752,130 for its EVM301 Series of carboxylated psilocybin derivatives. This patent is significant as it pertains to potential treatments for mental health disorders, potentially strengthening the company's market position in this therapeutic area.
Read more →ENVBEnveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
Enveric Biosciences has announced the issuance of U.S. Patent No. 11,752,130 for its EVM301 Series, which includes novel carboxylated psilocybin derivatives. This patent enhances the company's intellectual property rights and supports its development of therapies targeting mental health disorders. The EVM301 Series is designed to promote neuroplasticity without causing hallucinations, potentially revolutionizing treatment options for depression and anxiety.
Read more →ENVBEnveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates Claims to novel composition of matter and pharmaceutical drug fo
Enveric Biosciences has announced the issuance of a new U.S. patent for its EVM301 Series, which includes novel carboxylated psilocybin derivatives intended for treating various mental health disorders. The patent, issued by the United States Patent and Trademark Office, provides protections for unique drug formulations that enhance neuroplasticity without inducing hallucinations. This development is crucial for the commercialization of EVM301, which aims to offer a safe alternative for patients suffering from depression and anxiety. The company believes this advancement could change treatment paradigms in mental health therapy.
Read more →ENVBEnveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
Enveric Biosciences announced a poster presentation at the ICMBB 2023, showcasing its EVM301 Series, which focuses on non-hallucinogenic neuroplastogen drug candidates for mental health disorders. The presentation will detail novel screening processes and the potential therapeutic benefits of these compounds. The company aims to advance treatments for conditions like anxiety and depression without inducing hallucinations.
Read more →ENVBEnveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023 Poster details advances in screening for non-hallucinogenic, neuroplastogen drug
Enveric Biosciences is presenting a poster at the International Conference on Molecular Biology and Biochemistry 2023, showcasing their EVM301 Series which focuses on non-hallucinogenic neuroplastogen drug candidates. These candidates aim to treat mental health disorders, including depression and anxiety, by promoting neuroplasticity without inducing hallucinatory effects. The poster highlights the innovative screening processes used to synthesize these compounds and summarizes promising results from animal models. The company emphasizes advancements in their research platform and the potential impact on treating central nervous system disorders.
Read more →ENVBEnveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
Enveric Biosciences has filed a provisional patent application for AI-based methods to identify and optimize novel tryptamine derivatives. These methods aim to predict non-hallucinogenic compounds that interact with the 5-HT2A receptor, potentially offering effective treatments for anxiety, depression, and addiction. The application supports the development of compounds that could minimize side effects while promoting neuroplasticity.
Read more →ENVBEnveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives Enveric utilizing AI-backed 3D modeling to identify potential non-ha
Enveric Biosciences has announced the filing of a provisional patent application using AI to develop non-hallucinogenic tryptamine derivatives for treating anxiety, depression, and addiction. The new computational methods aim to optimize interactions with the 5-HT2A receptor, potentially minimizing unwanted hallucinogenic effects while addressing critical mental health conditions. This innovative approach could improve patient access to treatments while enhancing therapeutic outcomes. The company's efforts are focused on the development of their EVM301 Series, which seeks to provide a first-in-class therapeutic option.
Read more →ENVBEnveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
Enveric Biosciences has announced the issuance of U.S. Patent No. 11,746,087, which covers C4-carboxylic acid-substituted tryptamine derivatives. This patent strengthens the company's intellectual property for its lead candidate, EB-373, a psilocin prodrug aimed at treating anxiety disorders. The patent complements previous patents and supports Enveric's strategy to differentiate its products in the mental health space.
Read more →ENVBEnveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives New patent provides additional composition of matter and methods of use claims for Enveric's tryptamine-derived prod
Enveric Biosciences has announced the issuance of a new U.S. patent for C4-carboxylic acid-substituted tryptamine derivatives, which includes its lead candidate, EB-373. This composition enhances their intellectual property around psilocin prodrugs aimed at treating anxiety disorders. EB-373 is designed to offer rapid onset therapeutic effects with fewer side effects compared to traditional options. The patent addition is viewed as a strong pillar in Enveric's overall drug development strategy, which focuses on neuroplasticity and mental health treatment.
Read more →ENVBEnveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
Enveric Biosciences announced its participation in the H.C. Wainwright 25th Annual Global Conference, where CEO Joseph Tucker will present virtually. The conference will take place from September 11 to 13, 2023, and will include opportunities for one-on-one meetings with investors. An archived presentation will be available on the company's website after the event.
Read more →ENVBEnveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
Enveric Biosciences has announced the issuance of U.S. Patent No. 11,707,447 for its lead candidate EB-373, a psilocin prodrug aimed at treating anxiety disorders. This patent enhances the company's intellectual property rights, allowing for innovative modifications to tryptamine compounds that may improve therapeutic outcomes. EB-373 has demonstrated promising results in preclinical studies, indicating its potential effectiveness in mental health treatment.
Read more →ENVBEnveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs Composition of matter and methods of use claims encompass EB-373, Enveric's new chemical entity psiloci
Enveric Biosciences announced the issuance of a new U.S. patent for its lead candidate, EB-373, a psilocin prodrug aimed at treating anxiety disorders. This patent enhances the company's intellectual property rights, allowing for proprietary methods and compositions based on tryptamine-derived prodrugs. EB-373 is designed to offer a more rapid therapeutic effect while minimizing gastrointestinal side effects compared to traditional psilocin. The issuance of the patent is seen as a significant milestone for Enveric in advancing its innovative approach to mental health treatments.
Read more →ENVBEnveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
Enveric Biosciences has completed the manufacturing of EB-373, a prodrug aimed at treating anxiety disorders. The high purity of the product allows for efficient handling and shipping, eliminating restrictions associated with controlled substances. The company plans to initiate remaining GLP studies and aims to submit for human trials in Australia by the end of 2023.
Read more →ENVBEnveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program High purity of manufactured prodrug product allows Enveric and partners to ship EB-373 without being sub
Enveric Biosciences announced the completion of manufacturing for its lead drug candidate EB-373, a next-generation psilocin prodrug aimed at treating anxiety disorders. With a high purity of 99%, the drug can be shipped without the limitations associated with controlled substances, which is expected to enhance efficiency in the upcoming clinical trials. The company plans to commence the remaining GLP studies needed for Human Research Ethics Committee approval in Australia by the end of 2023, paving the way for initial human trials.
Read more →ENVBEnveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
Enveric Biosciences reported significant advancements in its preclinical pipeline for neuroplastogenic therapeutics aimed at mental health disorders. The company secured multiple patent allowances for its lead candidate, EB-373, and improved manufacturing processes. Despite a net loss of $6.40 million for Q2 2023, Enveric has implemented a cost reduction plan to extend its financial runway into early 2024.
Read more →ENVBEnveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results Advanced preclinical pipeline of neuroplastogenic small-molecule therapeutics targeting neuronal atrophy to offer a first-in-class treatment
Enveric Biosciences has made notable progress in its preclinical pipeline, focusing on neuroplastogenic small-molecule therapeutics for mental health disorders. The company secured several Notices of Allowance from the USPTO for its lead candidate, EB-373, and has improved its manufacturing processes. Despite reporting a significant loss in the second quarter of 2023, the company announced a cost reduction plan to extend its financial runway into early 2024. Enveric is on track to commence clinical trials for EB-373 and expects to identify another lead candidate by year-end.
Read more →ENVBEnveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373
Enveric Biosciences has reported positive results from preclinical studies of its lead candidate EB-373, demonstrating rapid conversion to the active metabolite psilocin. The studies align with previous animal pharmacokinetic results, indicating a favorable pharmacological profile. The company aims to progress EB-373 to human clinical trials, focusing on treating anxiety disorders with reduced side effects.
Read more →ENVBEnveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 Absorption, distribution, metabolism, and excretion (ADME) and toxicology assays demonstrated ra
Enveric Biosciences has announced positive results from preclinical studies of its lead candidate, EB-373, focusing on its absorption, distribution, metabolism, and excretion (ADME) and toxicology profiles. The studies demonstrated efficient conversion of EB-373 to its active metabolite, psilocin, showing consistent results across various animal models. These results support the potential for reduced side effects and shorter hallucinatory experiences compared to traditional psilocybin. Enveric plans to advance EB-373 into human clinical trials, aimed at treating anxiety disorders.
Read more →ENVBEnveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373
Enveric Biosciences reported positive results from pharmacokinetic studies of EB-373, a psilocin prodrug. The studies indicated that EB-373 has a favorable oral bioavailability and a rapid onset of action, with a well-tolerated side effect profile. Notably, it showed a dose-dependent increase in psilocin blood concentration without serious adverse effects. Enveric plans to present detailed findings at a future scientific conference.
Read more →ENVBEnveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373 Orally administered EB-373 resulted in dose-dependent increase in psil
Enveric Biosciences reported promising results from animal studies indicating that EB-373, a psilocin prodrug, is orally bioavailable and has a favorable side effect profile. The studies showed that EB-373 leads to a dose-dependent increase in psilocin blood levels, correlating with effective therapeutic concentrations expected in humans. Additionally, EB-373 demonstrated rapid conversion to the active metabolite and exhibited minimal side effects, such as gastrointestinal upset, compared to traditional psilocybin treatments. The company plans to present further analyses of these findings at an upcoming scientific conference.
Read more →ENVBEnveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
Enveric Biosciences announced two poster presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023) in Vancouver. The posters demonstrated research on psilocin prodrugs and MDMA derivatives, both aimed at addressing mental health disorders. The studies showed promising pharmacological properties that may lead to safer treatment options for patients. CEO Joseph Tucker expressed pride in the research contributions, which could significantly enhance therapeutic approaches in psychiatry.
Read more →ENVBEnveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates New composition of matter claims establish intellectual property for Enveric's EVM301 Series of novel small molecules desig
Enveric Biosciences has received a Notice of Allowance from the USPTO for its EVM301 Series of drug candidates, aimed at treating anxiety, depression, and addiction disorders. This patent includes composition of matter claims for novel tryptamine-based molecules designed to promote neuroplasticity without inducing hallucinations. The company believes these innovations could revolutionize mental health treatment and enhance the commercial viability of its products. Enveric is also planning to submit additional patent claims for the EVM301 Series in the near future.
Read more →ENVBEnveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023
Enveric Biosciences announced a poster presentation at the Canadian Neuroscience Meeting 2023, highlighting its research on the EVM201 and EVM301 Series. The work focuses on developing novel tryptamine-based therapeutics for anxiety, depression, and addiction disorders, aiming to reduce side effects linked to traditional psychedelics. Notably, machine-learning tools are being utilized to improve the candidate screening process. CEO Joseph Tucker expressed optimism about the research's implications for promoting neuroplasticity in mental health treatments.
Read more →ENVBEnveric Biosciences Receives Notice of Allowance from USPTO for C4-Carboxylic Acid-substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug New composition of matter claims expand intellectual property for
Enveric Biosciences has secured a Notice of Allowance from the USPTO for its EVM201 Series, which includes prodrug derivatives of psilocin. This is the second Notice of Allowance for this series, further strengthening the company's intellectual property portfolio. The new composition of matter claims are expected to provide advantages such as a quicker therapeutic effect and fewer gastrointestinal side effects compared to conventional treatments. Enveric is actively developing its EVM201 and EVM301 Series aimed at treating anxiety and depression without inducing hallucinations.
Read more →ENVBEnveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders Research highlights the potential of Enveric's EVM201 Series ai
Enveric Biosciences has announced the development of novel psilocin prodrugs as potential therapies for anxiety and other mental health disorders. The manuscript outlining this research highlights the creation of five unique prodrug derivatives from a library of compounds, aimed at reducing the psychedelic experience traditionally associated with psilocybin while maintaining therapeutic benefits. The lead candidate, EB-373, is designed for improved pharmacokinetic profiles and better therapeutic effects. The company has submitted this work for peer-reviewed publication and is optimistic about its implications for treating anxiety disorders.
Read more →ENVBEnveric Biosciences to Participate in 2023 BIO International Convention in Boston
Enveric Biosciences, Inc. (NASDAQ: ENVB) will participate in the 2023 BIO International Convention in Boston from June 5 to June 8. The company aims to discuss its portfolio of novel, patent-protected small molecule therapeutics aimed at treating anxiety, depression, and addiction disorders. Notably, the lead program, EB-373, is developed to address anxiety disorders without inducing hallucinations. The event marks a significant opportunity for Enveric to engage with pharmaceutical executives and potential investors.
Read more →ENVBEnveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin Intellectual property describes composition of matter claims governing Enveric's lead clinical candidate, EB-373, which is being d
Enveric Biosciences has announced receipt of a Notice of Allowance from the USPTO concerning its lead clinical candidate, EB-373, a psilocin prodrug aimed at treating anxiety disorder. This allows Enveric to pursue patent protection for novel chemical derivatives related to EB-373. The company aims to create a robust intellectual property portfolio as part of its strategy in developing therapeutics for mental health disorders. This development signifies positive momentum in Enveric's pipeline and the potential for a swift therapeutic effect from the prodrugs compared to traditional options.
Read more →ENVBEnveric Biosciences to Participate in Benzinga Psychedelics Capital Conference CEO Joseph Tucker, Ph.D., to discuss Enveric's pipeline and therapeutic opportunities in fireside chat and "NextGen Psychedelics" panel discu
Enveric Biosciences (NASDAQ: ENVB) will participate in the Benzinga Psychedelics Capital Conference, where CEO Joseph Tucker, Ph.D., will engage in a fireside chat and a panel discussion titled "NextGen Psychedelics." The company aims to showcase its pipeline and clinical development strategy, especially focusing on its lead candidate EB-373 for anxiety disorders. Meetings with potential investors will also be held to discuss the company's achievements and upcoming milestones.
Read more →ENVBEnveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results Key Highlights Nominated EB-373 as lead development candidate for the treatment of anxiety disorders EB-373 is a next generatio
Enveric Biosciences reported notable corporate and financial results for 2022, including the nomination of EB-373 as the lead candidate for anxiety disorders. The company established a subsidiary in Australia, preparing to initiate a Phase 1 trial for EB-373 by late 2023. Enveric also reported a significant net loss but has raised approximately $10 million through public offerings to support its initiatives. With advancements in their pipeline, the company aims to innovate mental health treatments, focusing on unmet needs in the CNS space.
Read more →ENVBEnveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373 EB-373, a proprietary psilocin prodrug, is on track to start its first-in-human clinical trial in the fourth quarter
Enveric Biosciences has selected Avance Clinical, an Australian contract research organization, to manage its upcoming Phase 1 clinical trial of EB-373. The trial, which is designed to assess the safety and tolerability of this psilocin prodrug, is scheduled to begin in the fourth quarter of 2023. EB-373 targets anxiety disorders and has been recognized as a New Chemical Entity by the Australian Therapeutic Goods Administration. Enveric's leadership expressed optimism about the potential impact of EB-373 on mental health treatment.
Read more →ENVBEnveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications First-in-human clinical trial investigating Enveric's lead product candidate,
Enveric Biosciences has launched Enveric Therapeutics Pty. Ltd., a subsidiary in Australia, to advance its lead psilocin prodrug, EB-373, focused on treating anxiety disorders. This move supports the initiation of a first-in-human clinical trial expected in late 2023. The Australian government provides an encouraging framework for biotech firms, enhancing the feasibility of early-stage product development. The company aims to leverage local regulations and expertise to expedite its clinical programs for EB-373 and other potential therapies.
Read more →ENVBEnveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery Research details the bioproduction of novel indolethylamine-type drug candidates with potential us
Enveric Biosciences has announced the development of a bioproduction platform using a newly isolated enzyme from the cane toad, aimed at producing novel indolethylamine-type drug candidates for psychiatric medicine. This groundbreaking research, undertaken by a team at the University of Calgary, could potentially lead to innovative treatments for anxiety, depression, and addiction. The company is moving forward with plans for clinical trials of their lead product, EB-373. The announcement highlights Enveric's unique approach in drug discovery, particularly in leveraging biological processes for therapeutic development.
Read more →ENVBEnveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 30+ year pharmaceutical industry veteran joins Enveric's executive team to lead com
Enveric Biosciences has appointed Kevin Coveney as Chief Financial Officer, effective March 13, 2023. Coveney brings over 30 years of experience in finance and operations from various biotechnology firms. His role will focus on leading the company's financial and capital markets activities, particularly concerning the development of the EVM201 and EVM301 therapeutic programs. Enveric believes Coveney's expertise will strengthen its financial discipline and support its growth objectives in the mental health therapeutics sector.
Read more →ENVBEnveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Accomplished pharmaceutical industry leader brings to Enveric extensive experi
Enveric Biosciences has announced the appointment of Lynn Gallant as Vice President of Clinical Operations, bringing extensive experience in clinical operations and product development. Gallant will oversee the company's EVM201 and EVM301 clinical programs and is set to lead the upcoming clinical trial for EB-373, a new treatment for anxiety disorders. This appointment follows her successful tenure at BlueRock Therapeutics, where she led various clinical programs. Enveric is focused on developing novel small-molecule therapeutics for mental health conditions.
Read more →ENVBEnveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules Cambridge, MA.
Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules MA., July 25, 2022 - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developin
Read more →ENVBEnveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines Internationally Recognized Neuroscience Experts Will Work Closely with Enveric Scien
Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines Recognized Neuroscience Experts Will Work Closely with Enveric Scientists to Help Drive Clinical Innovation and Success MA, July 19, 2022 - Enveric Bi
Read more →ENVBEnveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio - Advancing to IND-enabling studies with multiple drug candidates - - Enveric's Growing Patent Portfolio Val
Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio - Advancing to IND-enabling studies with multiple drug candidates - Patent Portfolio Validated - Cambridge, MA., July 13, 2022 - Enveric Biosciences, Inc. (NASDAQ
Read more →ENVBEnveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation p
Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative can
Read more →ENVBEnveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
Biosciences Announces Distribution of C Preferred Stock to Holders of its Common Stock Fla., May 3, 2022 - Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental
Read more →ENVBEnveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update
Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update Fla., March 31, 2022 - Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental he
Read more →ENVBEnveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates Patent Applications Aim to Expand Opportunities for Novel Therapeutics to Address a Broad Range of Psychiatri
Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates Applications Aim to Expand Opportunities for Novel Therapeutics to Address a Broad Range of Psychiatric and Neurological Disorders Fla., March 15, 2022 - Enveric Biosciences
Read more →ENVBEnveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules Robust Portfolio of Psychedelic-Inspired Molecules Positions Enveric to Achieve Global Patent Protection to potentially Cover Mill
Files Portfolio of Patent Applications for Robust Portfolio of Psychedelic-Inspired Molecules Positions Enveric to Achieve Global Patent Protection to potentially Cover Millions of Novel Pharmaceutical Candidates March 1, 2022 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric"
Read more →ENVBEnveric Biosciences Announces Proposed Public Offering
Biosciences Announces Proposed Public Offering Fla., Feb. 10, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health, and oncology treatments, today announced tha
Read more →ENVBEnveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate Target Indications include Osteoarthritis and Other Pain Conditions
Biosciences Announces Successful Synthesis and Filing of Patent for EV104 - Cannabinoid + Celecoxib Conjugate Indications include Osteoarthritis and Other Pain Conditions Fla., February 8, 2022 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience
Read more →ENVBEnveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders
Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders Fla., January 18, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company, today released a letter
Read more →ENVBEnveric Biosciences Announces Artificial Intelligence Platform, PsyAI TM , Has Identified Viable Drug Candidates from its Psybrary' of Psychedelic Molecular Compounds -Paving the way to select lead drug candidates for pr
Enveric Biosciences Announces Artificial Intelligence Platform, PsyAITM, Has Identified Viable Drug Candidates from its Psybrary' of Psychedelic the way to select lead drug candidates for preclinical studies to support clinical evaluation in cancer-related distress - NAPLES, F
Read more →ENVBEnveric Biosciences Announces Closing of MagicMed Industries Acquisition - Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress.
Biosciences Announces Closing of MagicMed Industries Acquisition intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress. Fla., September 17, 2021 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient
Read more →ENVBEnveric Biosciences Announces Approval from Israel's Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma Enveric Enters into Clinical Stage Development of Lead Asset, EV10
Biosciences Announces Approval from Israel's Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval Fla., July 8, 2021 - Enveric Biosciences (NASDAQ: ENVB) ("E
Read more →ENVBEnveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives. With
Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives. this acquisition, Enveric will expand and complement its pipeline of na
Read more →ENVBEnveric Biosciences Reports First Quarter 2021 Financial Results
Biosciences Reports First Quarter 2021 Financial Results Fla. - May 18, 2021 - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid (CBD) medicines to improve quality of life for cancer patient
Read more →ENVBEnveric Biosciences Appoints Carter Ward as Chief Financial Officer
Biosciences Appoints Carter Ward as Chief Financial Officer Fla. - April 12, 2021 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, toda
Read more →ENVBEnveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021 Strengthened balance sheet during the first quarter of 2021 with the closing of two direct offer
Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021 balance sheet during the first quarter of 2021 with the closing of two direct offerings totaling $22.8 million in gross proceeds and $3.3 million from the exercis
Read more →ENVBEnveric Biosciences Appoints Dr. Douglas D. Lind to Company's Board of Directors
Biosciences Appoints Dr. Douglas D. Lind to Company's Board of Directors Dr. Douglas Lind brings over 30 years of healthcare and capital markets experience to the board - YORK, March 18, 2021 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first bi
Read more →ENVBEnveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech - License has the Potential to Expand Enveric's Planned Capabilities to Address Cancer Treatment Side E
Biosciences Signs Definitive Agreement to Exclusive License for Novel Molecules from Diverse Biotech License has the Potential to Expand Enveric's Planned Capabilities to Address Cancer Treatment Side Effects - Innovative Conjugation Platform Aims to Provide Superior Therapeut
Read more →ENVBEnveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs Enveric and PureForm to Develop High-Quality, Consistent, Pure CBD Formulations an
Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs and PureForm to Develop High-Quality, Consistent, Pure CBD Formulations and Delivery Technology for Treating Pain and Inflammation Resulting from Ca
Read more →ENVBEnveric Biosciences, Inc. Announces Closing of $12.8 Million Registered Direct Offering of Common Stock NAPLES, FL
Biosciences, Inc. Announces Closing of $12.8 Million Registered Direct Offering of Common Stock FL, February 12, 2021 - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve
Read more →ENVBEnveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering NAPLES, FL
Biosciences Inc. Announces $12.8 Million Registered Direct Offering FL, February 9, 2021 - Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer pa
Read more →ENVBEnveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering
Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering Fla. - January 15, 2021 - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life
Read more →ENVBEnveric Biosciences Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules NAPLES, FL, January 12 th , 2021 - Enveric Biosciences Inc. (NASDAQ: ENVB), a patient-first biotechnology
Biosciences Inc. Announces $10 Million Registered Direct Offering At-the-Market under Nasdaq Rules FL, January 12th, 2021 - Enveric Biosciences Inc. (NASDAQ: ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for canc
Read more →ENVBEnveric Biosciences Appoints Dr. Marcus Schabacker to Board of Directors Industry Veteran Brings Over Three Decades of Experience Across Global Healthcare Landscape
Biosciences Appoints Dr. Marcus Schabacker to Board of Directors Veteran Brings Over Three Decades of Experience Across Global Healthcare Landscape Fla., Jan. 5, 2021 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechn
Read more →ENVBAMERI HOLDINGS ANNOUNCES 1-FOR-4 REVERSE STOCK SPLIT Immediately following the spin-off and the tender offer, Ameri Holdings to change its name to Enveric Biosciences, Inc. and will effect a 1-for-4 reverse stock split o
HOLDINGS ANNOUNCES 1-FOR-4 REVERSE STOCK SPLIT following the spin-off and the tender offer, Ameri Holdings to change its name to Enveric Biosciences, Inc. and will effect a 1-for-4 reverse stock split of its common stock Biosciences common stock to trade on NASDAQ Capital Mark
Read more →ENVBAMERI HOLDINGS' STOCKHOLDERS APPROVE ALL PROPOSALS TO COMPLETE TENDER OFFER FOR JAY PHARMA SHARES ATLANTA, GA - (
HOLDINGS' STOCKHOLDERS APPROVE PROPOSALS TO COMPLETE TENDER OFFER FOR JAY PHARMA SHARES GA - (December 29, 2020) - AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri", the "Company"), announced the voting results of the Special Meeting of stockholders that was held today. on the rep
Read more →ENVBJAY PHARMA, INC. UNAUDITED CONDENSED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019 TABLE OF CONTENTS Unaudited Condensed Balance Sheets 1 Unaudited Condensed Statements of Operations and Comp
CONDENSED FINANCIAL STATEMENTS FOR THE NINE ENDED SEPTEMBER 30, 2020 AND 2019 Unaudited Condensed Balance Sheets 1 Unaudited Condensed Statements of Operations and Comprehensive Loss 2 Unaudited Condensed Statements of Changes in Shareholders' Deficit 3 Unaudited Condensed Stat
Read more →ENVBAMERI HOLDINGS AMALGAMATION PARTNER JAY PHARMA REPORTS IRB APPROVAL FOR TESTING PROPRIETARY CBD FORMULATION IN BRAIN CANCER -Final Approval Anticipated in Summer 2020 to Initiate Phase I/II Study in Glioblastoma Multifor
HOLDINGS AMALGAMATION PARTNER JAY PHARMA REPORTS IRB APPROVAL FOR TESTING PROPRIETARY CBD FORMULATION IN BRAIN CANCER Approval Anticipated in Summer 2020 to Initiate Phase I/II Study in Glioblastoma Multiforme- GA - (June 2, 2020) - AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Com
Read more →ENVBAmeri Holdings to Merge with Jay Pharma Inc., Evidence-Based Cannabinoid Medicine & Wellness Company Focused on Cancer Jay Pharma holds exclusive license with Tikun Olam for cannabinoid intellectual property, including d
Ameri Holdings to Merge with Jay Pharma Inc., Evidence-Based Cannabinoid Medicine & Wellness Company Focused on Cancer ATLANTA, GA. and TORONTO, CANADA - January 13, 2020 -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri") today announced it entered into an amalgamation agreement
Read more →ENVBAMERI100 REGAINS COMPLIANCE WITH NASDAQ LISTING RULE 5550(A)(2) ATLANTA, GA.
AMERI100 REGAINS COMPLIANCE WITH NASDAQ LISTING RULE 5550(A)(2) ATLANTA, GA., December 13, 2019 -- AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), a specialized SAP cloud, digital and enterprise solutions company, announced today that it had received written notice from the
Read more →ENVBAMERI00 ANNOUNCES 1-FOR-25 REVERSE STOCK SPLIT TO REGAIN NASDAQ COMPLIANCE Common Stock to Begin Trading on a Split-Adjusted Basis at Market Open on Monday
AMERI00 ANNOUNCES 1-FOR-25 REVERSE STOCK SPLIT TO REGAIN NASDAQ COMPLIANCE Common Stock to Begin Trading on a Split-Adjusted Basis at Market Open on Monday, November 25, 2019 ATLANTA, November 22, 2019 (GLOBE NEWSWIRE) -- AMERI Holdings, Inc. (Nasdaq: AMRH) ("Ameri100"), a spe
Read more →ENVBAmeri Holdings Announces Adjournment of Annual Meeting of Stockholders until
Ameri Holdings Announces Adjournment of Annual Meeting of Stockholders until November 8, 2019 ATLANTA, GA., October 30, 2019 - AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri100"), a specialized SAP cloud, digital and enterprise solutions company, announced that its 2019 Annual Meet
Read more →ENVBAMERI HOLDINGS ANNOUNCES WARRANT EXCHANGE - Eliminates All Adverse Warrants - ATLANTA, GA.
AMERI HOLDINGS ANNOUNCES WARRANT EXCHANGE - Eliminates All Adverse Warrants - ATLANTA, GA., September 20, 2019 -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri100"), a specialized SAP cloud, digital and enterprise solutions company, today announced that it had exchanged all rema
Read more →ENVBAMERI Holdings Announces Exploration of Strategic Alternatives to Maximize Shareholder Value ATLANTA, Ga.
AMERI Holdings Announces Exploration of Strategic Alternatives to Maximize Shareholder Value ATLANTA, Ga., Aug. 26, 2019 (GLOBE NEWSWIRE) -- AMERI Holdings, Inc. (AMRH) ("Ameri100"), a specialized SAP cloud, digital and enterprise solutions company, today announced that its Boa
Read more →ENVBAMERI100 GRANTED 180-DAY
AMERI100 GRANTED 180-DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH BID PRICE RULE ATLANTA, GA., June 17, 2019 -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri100" or the "Company"), a specialized SAP cloud, digital and enterprise services company, announced that on June 11,
Read more →ENVBTo the Board of Directors and Management of Ameri Holdings, Inc.: I hereby resign from the board of directors (the "Board") effective as of
To the Board of Directors and Management of Ameri Holdings, Inc.: I hereby resign from the board of directors (the "Board") effective as of March 28, 2019. There were no disagreements between the company, management or the Board and myself relative to these resignations. Thank
Read more →ENVBAMERI100
AMERI100 ANNOUNCES CHANGES TO BOARD OF DIRECTORS ATLANTA, GA., December 12, 2018 -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri100" or the "Company"), a specialized SAP cloud, digital and enterprise services company, today announced the appointments of Founder and current Execu
Read more →ENVBAmeri100 Reports Second Consecutive Quarter of Year-Over-Year Adjusted EBITDA Profitability Third Consecutive Quarter of Sequential Gross Margin Improvement ATLANTA
Ameri100 Reports Second Consecutive Quarter of Year-Over-Year Adjusted EBITDA Profitability Third Consecutive Quarter of Sequential Gross Margin Improvement ATLANTA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri100" or the "Company"), a specia
Read more →ENVBAMERI100 APPOINTS BARRY KOSTINER CHIEF FINANCIAL OFFICER - Experienced Mergers and Acquisitions and Financial Management Executive to Help Drive Company's Next Stage of Growth - ATLANTA, GA.
AMERI100 APPOINTS BARRY KOSTINER CHIEF FINANCIAL OFFICER - Experienced Mergers and Acquisitions and Financial Management Executive to Help Drive Company's Next Stage of Growth GA., October 17, 2018 -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri100" or the "Company"), a special
Read more →ENVBAMERI100 ANNOUNCES $600,000 FollOW-On INVESTMENT IN CONNECTION WITH recently completed $6,000,000 Private Placement Atlanta, GA
ANNOUNCES $600,000 FollOW-On INVESTMENT IN CONNECTION WITH recently completed $6,000,000 Private Placement Atlanta, GA August 22, 2018 -- AMERI Holdings, Inc. (Nasdaq: AMRH) ("Ameri100" or the "Company), a specialized SAP cloud, digital, and enterprise services company, today
Read more →ENVBAMERI100 Announces results of 2018 annual meeting of stockholders ATLANTA, GA.
Announces results of 2018 annual meeting of stockholders ATLANTA, GA., August 17, 2018 -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri100" or the "Company"), a specialized SAP cloud, digital and enterprise services company, announced that stockholders voted in favor of all prop
Read more →ENVBAMERI100 reports POSITIve adjusted EBITDA FOR The Second quarter of 2018 - Achieves Profitability Goals on Improved Revenue Mix and Cost Reduction Initiatives - ATLANTA, GA.
reports POSITIve adjusted EBITDA FOR The Second quarter of 2018 - Achieves Profitability Goals on Improved Revenue Mix and Cost Reduction Initiatives - ATLANTA, GA., August 14, 2018 -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri100" or the "Company"), a specialized SAP cloud
Read more →ENVBAMERI100 ANNOUNCES $6,000,000 PRIVATE PLACEMENT Atlanta, GA
ANNOUNCES $6,000,000 PRIVATE PLACEMENT Atlanta, GA, July 25, 2018 -- AMERI Holdings, Inc. (Nasdaq: AMRH) ("Ameri100" or the "Company), a specialized SAP cloud, digital, and enterprise services company, today announced that it has entered into a securities purchase agreement wi
Read more →ENVBAMERI100 SECURES AMENDMENT TO PREFERRED STOCK AGREEMENT RESULTING IN AN ANTICIPATED $1.5 MILLION IN ANNUAL CASH SAVINGS Suwanee, GA
SECURES AMENDMENT TO PREFERRED STOCK AGREEMENT RESULTING IN AN ANTICIPATED $1.5 MILLION IN ANNUAL CASH SAVINGS Suwanee, GA, June 26, 2018 -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri100" or the "Company"), a specialized SAP cloud, digital and enterprise services company, to
Read more →ENVBAMERI100 announces first quarter 2018 financial results - Management to Host Conference Call Today at 8:30 a.m. ET (New York) - PRINCETON, N.J.
announces first quarter 2018 financial results - Management to Host Conference Call Today at 8:30 a.m. ET (New York) - PRINCETON, N.J., May 15, 2018 -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri100" or the "Company"), a specialized SAP cloud, digital and enterprise services
Read more →ENVBAMERI100 announces fourth quarter and full year 2017 financial results - Reaffirms Financial Target for Adjusted EBITDA Profitability during First-Half of 2018 - - Anticipates Adjusted EBITDA Profitability for 2018 - - M
announces fourth quarter and full year 2017 financial results - Reaffirms Financial Target for Adjusted EBITDA Profitability during First-Half of 2018 - - Anticipates Adjusted EBITDA Profitability for 2018 - Host Conference Call Today at 10:00 a.m. ET (New York) - PRINCETO
Read more →ENVBAMERI Holdings Promotes EVP Brent Kelton to CEO SAP Veteran to Lead Company in its Next Stage of Growth Company Reaffirms Financial Target for Adjusted EBITDA Profitability in First Half of 2018 PRINCETON, N.J.
AMERI Holdings Promotes EVP Brent Kelton to CEO Company in its Next Stage of Growth Company Reaffirms Financial Target for Adjusted EBITDA Profitability in First Half of 2018 PRINCETON, N.J., Dec. 27, 2017 /PRNewswire/ -- AMERI Holdings, Inc. ("Ameri100" or the "Company") (
Read more →ENVBAMERI Holdings Prices Public Offering and Lists on The Nasdaq Capital Market PRINCETON, N.J.
AMERI Holdings Prices PRINCETON, N.J., November 17, 2017 /PRNewswire/ -- AMERI Holdings, Inc. ("Ameri100" or the "Company") (NASDAQ: AMRH), a specialized SAP Cloud, Digital and Enterprise services company, today announced the pricing of an underwritten public offering of 1,475
Read more →ENVBAMERI Holdings, Inc. Announces Financial Results for the Third Quarter of 2017 Ameri Holdings continues to build its cloud, digital and enterprise SAP services capabilities PRINCETON, N.J., NOVEMBER 13, 2017 /PRNewswire/
AMERI Holdings, Inc. Announces Financial Results for the Third Quarter of 2017 Ameri Holdings continues to build its cloud, digital and enterprise SAP services capabilities PRINCETON, N.J., NOVEMBER 13, 2017 /PRNewswire/ -- AMERI Holdings, Inc. ("Ameri100" or the "Company")
Read more →ENVBEx. 99.1 AMERI Holdings, Inc. Announces Financial Results for the Second Quarter of 2017 Ameri Holdings continues to streamline and integrate acquired businesses to align with its cloud, digital and enterprise SAP servic
AMERI Holdings, Inc. Announces Financial Results for the Second Quarter of 2017 Ameri Holdings continues to streamline and integrate acquired businesses to align with its cloud, digital and enterprise SAP services, specifically focusing on SAP's futuristic technology investme
Read more →ENVBAMERI Holdings Announces Financial Results for Q1 2017 Strategic Partnership with NEC Corporation to provide SAP HANA Migration Services Successfully completed acquisition of ATCG an SAP Cloud Services Company PRINCETON,
AMERI Holdings Announces Financial Results for Q1 2017 Strategic Partnership with NEC Corporation to provide SAP HANA Migration Services Successfully completed acquisition of ATCG an SAP Cloud Services Company PRINCETON, N.J., MAY 16, 2017 /PRNewswire/ -- AMERI Holdings, I
Read more →ENVBAmeri100 Announces Appointment of Chief Financial Officer PR Newswire
Ameri100 Announces Appointment of Chief Financial Officer PR NewswireApril 25, 2017 PRINCETON, N.J., April 25, 2017 /PRNewswire/ -- AMERI Holdings, Inc. ("Ameri100" or the "Company") (AMRH), a leading integrated SAP solutions provider, today announced the appointment of Vira
Read more →ENVBAMERI Holdings Announces Financial Results for Q4 2016 and FY2016 Annual revenue in 2016 of over $36 million, up 78% over 2015 Successfully completed three strategic acquisitions of SAP services companies in 2016 bringin
AMERI Holdings Announces Financial Results for Q4 2016 and FY2016 Annual revenue in 2016 of over $36 million, up 78% over 2015 Successfully completed three strategic acquisitions of SAP services companies in 2016 bringing total acquisitions to eight since 2013 Ranked 5th in
Read more →ENVBAMERI100 Offers to Merge with CIBER Offer Price of $0.75 per CBR share Merger Would Create Platform for Margin Expansion and Value Creation PRINCETON, N.J.
PRINCETON, N.J., March 13, 2017 /PRNewswire/ -- AMERI Holdings, Inc. (OTC: AMRH) ("AMERI" or "Ameri100") announced today a merger proposal to CIBER, Inc. ("CIBER", "CBR", or the "Company") (NYSE: CBR) valuing CBR at a price of $0.75 per share, which is a substantial premium to CB
Read more →ENVBAmeri100 acquires ATCG, a SAP Cloud services firm PRINCETON, N.J.
ATCG, a SAP Cloud services firm PRINCETON, N.J., March 10, 2017 /PRNewswire/ -- AMERI Holdings, Inc. ("Ameri100" or the "Company") (AMRH), today announced the acquisition of ATCG Solutions ("ATCG"), a system integration firm specializing in providing end-to-end SAP Enterprise
Read more →ENVBto Ameri100's report on Form 8-K filed with the Securities and Exchange Commission on
Holdings, Inc. Reports Financial Results for the Third Quarter and Nine Months ended September 30, 2016 N.J., Nov. 14, 2016 /PRNewswire/ -- AMERI Holdings, Inc. ("Ameri100" or the "Company") (OTCQB: AMRH), today reported its financial results for the third quarter and nine mon
Read more →ENVBAmeri100 Completes Acquisition of SAP Consulting Firm DC&M Partners, L.L.C. Acquisition reinforces Ameri100's leadership in SAP consulting services Princeton, NJ
Ameri100 Completes Acquisition of SAP Consulting Firm DC&M Partners, L.L.C. Acquisition reinforces Ameri100's leadership in SAP consulting services Princeton, NJ, August 1, 2016 / PR Newswire - AMERI Holdings, Inc. ("Ameri100" or the "Company") (OTCQB: AMRH), today announced
Read more →ENVBAmeri100 completes acquisition of SAP consulting firm Virtuoso Acquisition reinforces Ameri100's leadership in SAP S/4 HANA Finance Princeton, NJ
Ameri100 completes acquisition of SAP consulting firm Virtuoso Acquisition reinforces Ameri100's leadership in SAP S/4 HANA Finance Princeton, NJ, July 25, 2016/ PR Newswire- AMERI Holdings, Inc. ("Ameri100" or the "Company")(OTCQB: AMRH), today announced the acquisition of Vir
Read more →ENVBAmeri100 Secures $10 Million Financing with Sterling National Bank Princeton, NJ
Ameri100 Secures $10 Million Financing with Sterling National Bank Princeton, NJ, July 6, 2016/ PR Newswire - AMERI Holdings, Inc. ("Ameri100" or the "Company") (OTCQB: AMRH), a SAP-based strategy consulting firm that brings synergies of classic technology consulting and product
Read more →ENVBAmeri100 acquires SAP consulting firm Bigtech Software Princeton, NJ
Ameri100 acquires SAP consulting firm Bigtech Software Princeton, NJ, June 29, 2016/ PR Newswire - AMERI HOLDINGS, Inc. ("Ameri100" or the "Company") (OTCQB: AMRH), an SAP strategy consulting firm that brings synergies of classic technology consulting and product-based technolog
Read more →ENVBAmeri100 Appoints former Infosys CFO as New Board Member Princeton, NJ
Ameri100 Appoints former Infosys CFO as New Board Member Princeton, NJ, June 28, 2016/ Online PR News- AMERI HOLDINGS, Inc. ("Ameri100" or the "Company") (OTCQB: AMRH), is pleased to announce the addition of Mr. Venkatraman "Bala" Balakrishnan, as a new member to its board of di
Read more →ENVBAmeri Holdings, Inc. Announces Completion of Private Placement PRINCETON, NJ
Ameri Holdings, Inc. Announces Completion of Private Placement PRINCETON, NJ, April 21, 2016 /PRNewswire/ - AMERI HOLDINGS, Inc. ("Ameri100" or the "Company") (OTCQB: AMRH), is pleased to announce that it closed a $3.0 million private placement financing yesterday with the issua
Read more →ENVBAMERI Holdings, Inc. Announces Appointment of New Chief Financial Officer PRINCETON, NJ
AMERI Holdings, Inc. Announces Appointment of New Chief Financial Officer PRINCETON, NJ, January 28, 2016 /PRNewswire/ - AMERI HOLDINGS, Inc. ("Ameri100" or the "Company") (OTCQB: AMRH), a strategy consulting firm that brings synergies of classic technology consulting and produc
Read more →ENVBAMERI Holdings Reports Financial Results for the Quarter Ended
AMERI Holdings Reports Financial Results for the Quarter Ended September 30, 2015 Issues 2016 Guidance and Provides Operational and Product Updates PRINCETON, NJ, November 23, 2015/PRNewswire/ - AMERI HOLDINGS, Inc. ("Ameri100" or the "Company") (OTCQB: AMRH), a strategy consul
Read more →ENVBAMERI Holdings, Inc. Completes Acquisition of Bellsoft, Inc. Transaction Reinforces AMERI's Acquisition Strategy & Demonstrates Its Rapid Growth In The IT Services & Consulting Industry Princeton, NJ
AMERI Holdings, Inc. Completes Acquisition of Bellsoft, Inc. Transaction Reinforces AMERI's Acquisition Strategy & Demonstrates Its Rapid Growth In The IT Services & Consulting Industry Princeton, NJ, November 20, 2015 /PRNewsire/ - Transaction Highlights: AMERI Holdings, In
Read more →ENVBAmeri and Partners Inc. and Subsidiaries Consolidated Financial Statements Year Ended
Ameri and Partners Inc. and Subsidiaries Consolidated Financial Statements Year Ended March 31, 2015 and For the Period From November 27, 2013 (Date of Inception) to March. 31, 2014 Ameri and Partners Inc. and Subsidiaries Report of Independent Registered Public Accounting F
Read more →ENVBAMERI Holdings, Inc. Becomes a Public Company Completes Private Placement of up to $10 Million with Lone Star Value EDISON, N.J.
AMERI Holdings, Inc. Becomes a Public Company Completes Private Placement of up to $10 Million with Lone Star Value EDISON, N.J., May 26, 2015 - Transaction Highlights: AMERI Holdings, Inc. ("Ameri100" or the "Company"), formerly Spatializer Audio Laboratories, Inc. (OTCQB: S
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. spatializeraudiolabs@yahoo.com SPATIALIZER AUDIO LABORATORIES DECLARES CASH DIVIDEND Dividend of $0.021 per Share to be Paid to
CONTACT: INVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. spatializeraudiolabs@yahoo.com AUDIO LABORATORIES DECLARES CASH DIVIDEND of $0.021 per Share to be Paid to Common Stockholders of Record on April 15, 2008 Los Angeles, Calif., April
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. spatializeraudiolabs@yahoo.com SPATIALIZER AUDIO LABORATORIES ANNOUNCES YEAR END AND FOURTH QUARTER FINANCIAL RESULTS Los Angele
CONTACT: INVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. spatializeraudiolabs@yahoo.com SPATIALIZER AUDIO LABORATORIES ANNOUNCES YEAR END AND FOURTH QUARTER FINANCIAL Los Angeles, Calif., March 31, 2008- Spatializer Audio Laboratories
Read more →ENVBSpatializer Audio Laboratories Announces Second Quarter Financial Results LOS ANGELES, Aug. 10 /PRNewswire-FirstCall/ Spatializer Audio Laboratories, Inc. (OTC Bulletin Board: SPAZ) (the Company ) announced its financial
Spatializer Audio Laboratories Announces Second Quarter Financial Results LOS ANGELES, Aug. 10 /PRNewswire-FirstCall/ Spatializer Audio Laboratories, Inc. (OTC Bulletin Board: SPAZ) (the Company ) announced its financial results for the second quarter ended Revenues increased
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. spatializeraudiolabs@yahoo.com SPATIALIZER AUDIO LABORATORIES CONSUMATES SALE OF ASSETS Los Angeles, Calif.
CONTACT: INVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. spatializeraudiolabs@yahoo.com SPATIALIZER AUDIO LABORATORIES CONSUMATES Los Angeles, Calif., July 2, 2007- Spatializer Audio Laboratories, Inc. (OTC Bulletin Board: SPAZ) (the Compa
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. investor@spatializer.com SPATIALIZER AUDIO LABORATORIES ANNOUNCES FIRST QUARTER FINANCIAL RESULTS Los Angeles, Calif.
CONTACT: INVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. investor@spatializer.com SPATIALIZER AUDIO LABORATORIES ANNOUNCES FIRST QUARTER FINANCIAL RESULTS Los Angeles, Calif., May 10, 2007- Spatializer Audio Laboratories, Inc. (OTC Bulleti
Read more →ENVBSource: Spatializer Audio Laboratories, Inc. Spatializer Audio Laboratories Announces Year End and Fourth Quarter Financial Results Wednesday March 28, 8:30 am ET LOS ANGELES, March 28 /PRNewswire-FirstCall
Spatializer Audio Laboratories Announces Year End and Fourth Quarter Financial Results Wednesday March 28, 8:30 am ET LOS ANGELES, March 28 /PRNewswire-FirstCall/ Spatializer Audio Laboratories, Inc. (OTC Bulletin Board: SPAZ News; the Company ) announced its financial results
Read more →ENVBexv99w1 Spatializer Audio Laboratories Announces Results of Stockholder Vote LOS ANGELES, Feb. 22 /PRNewswire-FirstCall/ Spatializer Audio Laboratories, Inc. (OTC Bulletin Board: SPAZ News; the Company ) announced that i
Spatializer Audio Laboratories Announces Results of Stockholder Vote LOS ANGELES, Feb. 22 /PRNewswire-FirstCall/ Spatializer Audio Laboratories, Inc. (OTC Bulletin Board: SPAZ News; the Company ) announced that its previously adjourned annual meeting of stockholders reconvened
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. investor@spatializer.com SPATIALIZER AUDIO LABORATORIES ADJOURNS ANNUAL MEETING TO EXTEND VOTING ON ASSET SALE Los Angeles, Cali
CONTACT: INVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. investor@spatializer.com SPATIALIZER AUDIO LABORATORIES ADJOURNS ANNUAL MEETING TO EXTEND VOTING ON ASSET SALE Los Angeles, Calif., January 25, 2007- Spatializer Audio Laboratories, I
Read more →ENVBexv99w1 CONTACT: INVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. investor@spatializer.com SPATIALIZER AUDIO LABORATORIES, INC. REPORTS THIRD QUARTER OPERATING RESULTS San Jose, Calif.
CONTACT: INVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. investor@spatializer.com SPATIALIZER AUDIO LABORATORIES, INC. REPORTS THIRD QUARTER OPERATING RESULTS San Jose, Calif., November 14, 2006- Spatializer Audio Laboratories, Inc. (OTC B
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell Spatializer Audio Laboratories, Inc. investor@spatializer.com FOR RELEASE AT 8 A.M. EDT " --> FOR RELEASE AT 8 A.M. EDT Spatializer Audio Laboratories Announces Signing of Def
CONTACT: INVESTOR RELATIONS Spatializer Audio Laboratories, Inc. investor@spatializer.com FOR RELEASE AT 8 A.M. EDT Spatializer Audio Laboratories Announces Signing of Definitive Asset Purchase Agreement Subject to Stockholder Approval JOSE, Calif., September 19, 2006 Spat
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. investor@spatializer.com SPATIALIZER AUDIO LABORATORIES, INC. REPORTS SECOND QUARTER OPERATING RESULTS San Jose, Calif.
CONTACT: INVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. investor@spatializer.com SPATIALIZER AUDIO LABORATORIES, INC. REPORTS SECOND QUARTER OPERATING RESULTS San Jose, Calif., August 14, 2006- Spatializer Audio Laboratories, Inc. (OTC Bu
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. investor@spatializer.com SPATIALIZER AUDIO LABORATORIES, INC. REPORTS FIRST QUARTER OPERATING RESULTS San Jose, Calif.
CONTACT: INVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. investor@spatializer.com SPATIALIZER AUDIO LABORATORIES, INC. REPORTS FIRST QUARTER OPERATING RESULTS San Jose, Calif., May 15, 2006- Spatializer Audio Laboratories, Inc. (OTC Bullet
Read more →ENVBTO BUSINESS AND TECHNOLOGY EDITORS: Spatializer Audio Laboratories Inc. Reports Year End Results SAN JOSE, Calif., March 29 /PRNewswire-FirstCall/ Spatializer Audio Laboratories Inc. (OTC Bulletin Board: SPAZ) today repo
TO BUSINESS AND TECHNOLOGY EDITORS: Spatializer Audio Laboratories Inc. Reports Year End Results SAN JOSE, Calif., March 29 /PRNewswire-FirstCall/ Spatializer Audio Laboratories Inc. (OTC Bulletin Board: SPAZ) today reported revenues of $1,192,000 for the year ended December
Read more →ENVBexv99w1 CONTACT: INVESTOR RELATIONS Henry R. Mandell Spatializer Audio Laboratories, Inc. 408-453-4180 Ext. 201 E-mail: investor@spatializer.com FOR RELEASE AT 8 A.M. EST Spatializer Audio Laboratories Will Extend Evalua
CONTACT: INVESTOR RELATIONS Spatializer Audio Laboratories, Inc. 408-453-4180 Ext. 201 E-mail: investor@spatializer.com FOR RELEASE AT 8 A.M. EST Spatializer Audio Laboratories Will Extend Evaluation and Due Diligence Period for Sale of Assets and Perpetual License Grants S
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. 408-453-4180 Ext. 201 E-mail: investor@spatializer.com FOR RELEASE AT 8 A.M. EST Spatializer Audio Laboratories Unveils Details
CONTACT: INVESTOR RELATIONS Henry R. Mandell, Chairman Spatializer Audio Laboratories, Inc. 408-453-4180 Ext. 201 E-mail: investor@spatializer.com FOR RELEASE AT 8 A.M. EST Spatializer Audio Laboratories Unveils Details on Sale of Assets and Perpetual License Grants Subjec
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell Spatializer Audio Laboratories, Inc. 408-453-4180 Ext. 201 E-mail: investor@spatializer.com FOR RELEASE AT 8 A.M. EST Spatializer Audio Laboratories Announces Resignations Com
CONTACT: INVESTOR RELATIONS Spatializer Audio Laboratories, Inc. 408-453-4180 Ext. 201 E-mail: investor@spatializer.com FOR RELEASE AT 8 A.M. EST Spatializer Audio Laboratories Announces Resignations Company to Pursue Strategic Transaction SAN JOSE, Calif., December 22, 20
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, CEO Spatializer Audio Laboratories, Inc. 408-453-4180 Ext.201 investor@spatializer.com For release at 8 a.m. EST SPATIALIZER AUDIO LABORATORIES, INC. REPORTS CONTINUED GROWTH
CONTACT: INVESTOR RELATIONS Henry R. Mandell, CEO Spatializer Audio Laboratories, Inc. 408-453-4180 Ext.201 investor@spatializer.com For release at 8 a.m. EST SPATIALIZER AUDIO LABORATORIES, INC. REPORTS CONTINUED GROWTH AND PROFITABILITY Revenues Increase 32% Over the Pr
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, CEO Spatializer Audio Laboratories, Inc. 408-453-4180 Ext.201 investor@spatializer.com SPATIALIZER AUDIO LABORATORIES, INC. REPORTS CONTINUED PROFITABILITY IN THE SECOND QUAR
CONTACT: INVESTOR RELATIONS Henry R. Mandell, CEO Spatializer Audio Laboratories, Inc. 408-453-4180 Ext.201 investor@spatializer.com SPATIALIZER AUDIO LABORATORIES, INC. REPORTS CONTINUED PROFITABILITY IN THE SECOND Revenues Increase 83% Over the Prior Year San Jose, Cali
Read more →ENVBINVESTOR RELATIONS Henry R. Mandell, CEO Spatializer Audio Laboratories, Inc. 408-453-4180 Ext.201 investor@spatializer.com SPATIALIZER AUDIO LABORATORIES, INC. REPORTS PROFITABLE FIRST QUARTER 2005 OPERATING RE
CONTACT: INVESTOR RELATIONS Henry R. Mandell, CEO Spatializer Audio Laboratories, Inc. 408-453-4180 Ext.201 investor@spatializer.com SPATIALIZER AUDIO LABORATORIES, INC. REPORTS PROFITABLE FIRST QUARTER 2005 OPERATING RESULTS Year Over Year Revenues Increase 94% San Jose,
Read more →ENVBexv99w1 CONTACT: INVESTOR RELATIONS Henry R. Mandell, CEO Spatializer Audio Laboratories, Inc. 408-453-4180 Ext.201 E-mail: investor@spatializer.com For Release 7:30 am EST
CONTACT: INVESTOR RELATIONS Henry R. Mandell, CEO Spatializer Audio Laboratories, Inc. 408-453-4180 Ext.201 E-mail: investor@spatializer.com For Release 7:30 am EST March 23, 2005: Spatializer Audio Laboratories Inc. Returns to Profitability in Fourth Quarter Fiscal 2004 N
Read more →ENVBSPATIALIZER AUDIO LABORATORIES, INC. LOGO] CONTACT: INVESTOR RELATIONS Spatializer Audio Laboratories, Inc. 408-453-4180 ext 4 E-mail: investor@spatializer.com FOR RELEASE NOVEMBER 11, 2004: SPATIALIZER AUDIO LABORATORIE
[SPATIALIZER AUDIO LABORATORIES, INC. LOGO] CONTACT: INVESTOR RELATIONS Spatializer Audio Laboratories, Inc. E-mail: investor@spatializer.com FOR RELEASE NOVEMBER 11, 2004: SPATIALIZER AUDIO LABORATORIES, INC. NARROWS THIRD QUARTER LOSS COMPARED TO PRIOR QUARTERS CASH POSI
Read more →ENVBSPATIALIZER AUDIO LABORATORIES, INC. LOGO] CONTACT: INVESTOR RELATIONS Henry R. Mandell, CEO Spatializer Audio Laboratories, Inc. 408-453-4180 Ext. 4 E-mail: investor@spatializer.com Spatializer Audio Laboratories Conclu
[SPATIALIZER AUDIO LABORATORIES, INC. LOGO] CONTACT: INVESTOR RELATIONS Henry R. Mandell, CEO Spatializer Audio Laboratories, Inc. E-mail: investor@spatializer.com Spatializer Audio Laboratories Concludes Major Multi-Technology Licensing Agreement with Samsung Electronics
Read more →Competitive Position
How ENVB ranks across every disease it competes inCompetitive Position is a premium feature
See how ENVB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial